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Abstract
In the past decades, many new and interesting modalities for therapeutics have
been discovered, including nucleic acid therapeutics such as siRNA and mRNA.
However, one of the limiting challenges in developing these technologies into medicines
is delivering the therapeutics to the correct location in the body or in the cell. Furthermore,
many older modalities for therapeutics, such as vaccines and chemotherapeutics, could
become more efficacious with optimization of delivery. By using chemical engineering
principles, we can develop better delivery methods, materials, and formulations to
improve the treatment of a wide range of diseases. In this thesis, I report on applications
to vaccines and cancer.
Vaccines are currently the vanguard of public health efforts; unfortunately, a wide
range of diseases have no effective vaccine. This includes devastating diseases such as
HIV, malaria, and others. One area of vaccination that few people have considered
optimizing is the kinetics by which the vaccine is delivered. We found that using an
exponential increasing dosing profile, we could produce over 7 times more antibodies
compared to the current prime-boost profile using the same amount and type of vaccine.
The antibodies generated were also of higher affinity. By improving antibody affinity and
titer, this work may make existing vaccines for diseases such as HIV sufficiently
efficacious to use in humans.
Cancer is one of the leading causes of death in both developed and developing
countries, and is extremely difficult to cure due to its high variability. Furthermore, current
cancer therapeutics cause severe toxicity. By delivering more of the cancer therapeutics
to the tumor, we can reduce the side effects. Some tumors, because of their location, are
even harder to access: brain tumors, such as glioblastoma, are protected from most drugs
by the blood-brain barrier or blood-brain-tumor barrier. Circumventing these challenges
allow us to develop safer and more efficacious therapies. We found that conjugates of
siRNA with chlorotoxin could knock down levels of a housekeeping gene in vitro and in
vivo in a mouse brain tumor model. Furthermore, we developed prostate-cancer targeting
ligands that demonstrate in vitro efficacy and tested them in vivo.
Thesis Supervisor: Daniel G. Anderson
Title: Associate Professor of Chemical Engineering
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Chapter 1: Introduction
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Overview
The central dogma of biology is as follows: DNA is transcribed into RNA, which is
translated into protein, which has a wide range of activities. From ancient times until now,
people have focused on interfering somewhere along this path (knowingly or
unknowingly) to treat disease and improve health (1). This process began with plants that
contained beneficial small molecules, and has now advanced to small molecule inhibitors
of specific proteins, nucleic acid therapies that can modulate a wide variety of genes,
protein therapies that interact and signal with other proteins, and even cell-based
therapies that can replicate and make decisions (2-5). However, despite our advances in
creating new and ever more potent therapeutic modalities, a basic challenge remains that
we have yet to be able to overcome: the challenge of directing the therapeutic to the right
location in the body or even in the cell (6). This is what the field of drug delivery has set
out to do, and the challenges are manifold.
Most small molecule drugs permeate the entire body, and if the drug acts outside
of the targeted location, there could be toxicities or other side effects (6). As an example,
chemotherapeutics are drugs that target physiological processes that affect rapidly-
dividing cells the most (7). This indeed causes irreparable damage to cancer cells;
however, it also wipes out certain immune cell populations, such as neutrophils, leading
to deadly infections (8). It also affects hair stem cells, leading to the telltale balding of
chemotherapy patients (8). The ability to direct chemotherapeutics only to cancer cells
would revolutionize cancer treatment-higher doses would lead to more complete
eradication of the tumors without causing toxic side effects.
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Instead of causing toxic effects, some drugs lose their efficacy when they are not
in the correct location. Nucleic acid drugs include small interfering RNAs that can knock
down any gene, mRNAs that can upregulate any protein, and DNA gene therapies that
can insert new genes or fix current ones (3). However, if these therapeutics do not reach
the cytoplasm (RNA) or nucleus (DNA) of sufficient numbers of diseased cells, they will
not have any effect (9). There are many barriers in the way of these therapeutics: first,
the nucleic acid, typically injected intravenously, needs to survive the bloodstream and
avoid endonucleases that seek to protect your body from viruses. Secondly, the molecule
must leave the bloodstream at the correct site to enter the tissue of interest. Thirdly, the
molecule must somehow identify the correct cell type. Lastly, the molecule must cross
one or more lipid membranes in order to get inside the cell or nucleus (9). This is
especially difficult for nucleic acid molecules as they are heavily negatively charged,
which renders them unable to cross lipid membranes. Because of these challenges, very
few of these therapeutics have reached clinical stage and none of these types of therapies
have yet been approved by the FDA (10).
Besides simple molecular therapies, these ideas can also be used to improve more
complex therapeutic interventions, such as cell therapies and vaccinations. In the case of
vaccinations, understanding where, when, and how the antigen is passed around in the
system allows one to develop better ways to induce antibodies as well as cytotoxic T-cell
responses against infectious diseases and cancer(1 1, 12). Longer or controllable dosage
forms of drugs lead to better patient experiences and can increase efficacy and safety.
Furthermore, cell therapies need to be directed to the correct location in order to have
maximal effect and minimal off-target effects. As an example, chimeric antigen receptor
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T (CAR-T) cells are effective and have been approved for certain lymphomas, but have
been associated with a wide range of off-target toxicities that can even lead to death (13,
14).
In summary, delivering therapeutics to the correct location at the right time is a
great challenge for many therapeutics, ranging from simple small molecules to more
complex proteins and even cell-based therapies. Successfully doing so would allow many
novel therapeutics to reach their full potential. In this Introduction, I will review
fundamental principles of drug delivery, highlight examples of current methods of drug
delivery, and examine new ways to deliver certain types of compounds.
Principles of Drug Delivery
Drug delivery is the field of getting therapeutics to where they are needed in the
body. We can consider this through the dimensions of space and time. Spatially, we are
concerned with where the therapeutic reaches in the body. This could include delivery to
certain tissues, organs, or even within certain cells. Temporally, we are interested in how
concentrations build and decrease in certain parts of the body, and how we can optimize
these profiles. Many of these ideas have been derived from pharmacology.
Pharmacokinetics (PK) is the study of how drugs move within the body, and
pharmacodynamics (PD) is the study of how drugs are transformed and act within
different places (15). By studying ways of modifying PK/PD properties of drugs, we can
change where they go. These types of studies are typically done by analyzing distribution
within animals in vivo using drug labeled with radioactive elements, fluorescent
molecules, or antibody tags (16). Other measures of interest include the kinetics of the
drug in key compartments of the body, such as the bloodstream.
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The goal of modifying delivery and changing PK/PD is to improve the therapeutic
window. This is the range of doses between the minimum effective dose (MED) of the
drug and the maximal tolerable dose (MTD) of the drug. There are two ways of doing so:
decreasing the efficacious dose, or increasing the MTD. Using cancer as an example, if
we double the amount of the drug that reaches the tumor, we can halve the efficacious
dose, which greatly improves the therapeutic window (17). Likewise, having more of a
drug circulating in an encapsulated form could reduce kidney toxicity without changing
the effective dose (18).
Strategies for Spatial control of therapeutics
Broadly speaking, there are two routes one could use for delivering therapeutics:
firstly, we can release a compound locally, in order to have maximum concentration at
some area of the body. Secondly, we could consider introducing a compound in some
other part of the body. This could be done orally, in the bloodstream, or into some other
compartment: muscle, under the skin, the peritoneum, or even spinal cord. Each of these
methods have tradeoffs between invasiveness and ability to get drug into the desired
location(19, 20). Furthermore, each has different kinetics in terms of how long and when
therapeutics are delivered.
Oral delivery has traditionally been fairly popular, due to its ease of administration.
However, compounds undergo metabolism in the microbiome and the liver, and thus may
change (21). Furthermore, bloodstream availability is often poor, especially for larger
molecules (22). Direct injection into the bloodstream has immediate bloodstream
bioavailability, but also increases biodistribution to organs such as liver, kidney, and
spleen, which may experience toxicity (23).
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Many methods have been invented to deliver therapeutics to the correct location
or modify its biodistribution. This has been useful in a wide variety of applications, ranging
from cancer to wound healing(7, 24). In this section, I review some of the more common
systems that have been tried in the past. These include encapsulation inside or
conjugation onto nanoparticles, chemical modification/conjugation of ligands, and a
variety of methods for local delivery.
Nanoparticle carriers
A wide variety of therapeutics can be encapsulated into or onto nanoparticles.
These include small molecules, nucleic acids, and proteins (25-27). Nanoparticles are
able to change the size, shape, and chemical interactions of the therapeutic relative to its
environment, thus enabling delivery to different or more selective locales than the drug
alone (28, 29). In some cases, nanoparticles can also protect the drug from degradation
(9). Thus, encapsulation in nanoparticles has been adopted as one of the primary
methods for modulating the biodistribution of a wide variety of therapeutics.
Nanoparticles come in a wide variety of shapes and sizes, and can be made from
many different types of materials. Some of the more common nanoparticles are gold
nanoparticles, magnetic nanoparticles, quantum dots, polymer nanoparticles, and
liposomes. Gold nanoparticles come in a wide range of shapes, including spheres, rods,
shells, and cages (30). Because of its inert nature, gold nanoparticles are well tolerated
and non-toxic(31). They can be manufactured using a one-pot method and react with
sulfur moieties, which allows for a wide range of bioconjugation strategies (31). They can
be functionalized with a wide range of molecules, including antibiotics, cancer drugs, and
larger molecules such as nucleic acids and antibodies (30, 31). Besides therapeutic
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moieties, they can be coated with targeting molecules to further direct them to certain
locations in the body (30, 32). Furthermore, in the context of cancer, they can be irradiated
with radio- or microwaves to generate heat, which can be used to locally ablate cancer
(32). These systems are already in clinical trials (32).
Magnetic nanoparticles are typically made from superparamagnetic iron oxide
nanocrystals (33). They maintain magnetic properties, and thus can be guided with
magnets or used as contrast agents for MRIs (34). Magnetic nanoparticles can be
synthesized with a wide range of methods, including mechanical attrition and chemical
synthesis (35). After synthesis, in order to protect the particles and provide reactive
handles for bioconjugation, magnetic nanoparticles are typically coated with polymers or
lipids. Typical coatings include PEG, chitosan, dextran, PEI, and phospholipids (for
formulation into liposomes and micelles) (35). Drug and targeting moieties can then be
added to the coatings to create a therapeutic or diagnostic agent (33, 35). A wide range
of therapeutic modalities primarily for use in cancer treatment have been attached to
magnetic nanoparticles, including small molecules, proteins, and nucleic acid drugs (34).
For applications close to the surface, magnetic field gradients can be used to guide the
nanoparticles towards a target (34). As contrast agents, magnetic nanoparticles have
been used to illuminate tumors with MRI due to its effect on local proton relaxation (34).
They can be targeted using the enhanced permeation and retention effect, where tumors
exhibit leaky vasculature and accumulate nanoparticles, and also through the direct
conjugation of active targeting moieties, such as antibodies and other proteins (34).
Polymer nanoparticles have also been used for drug delivery. They can be made
from a wide range of polymers, ranging from non-biodegradable polymers such as
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polymethylmethacrylate and polystyrene, to biodegradable polymers including polylactic
acid and chitosan (25, 36). Because of the wide range of polymers used and their differing
biological activities, toxicity can be a problem for certain types of polymeric nanoparticles,
especially those constructed out of non-biodegradable materials (36). Polymeric
nanoparticles can be made into a wide range of shapes and sizes, including spherical
particles, thin rods, polymer brushes, and micelles (36). Their versatility allows for
encapsulation or conjugation of a wide range of therapeutic entities, including small
molecules, proteins, and nucleic acids (36). For nucleic acid delivery in particular, cationic
polymers enable the negatively-charged nucleic acids to form stable complexes. These
complexes protect the nucleic acids and also enhance transfection efficacy. In order to
change the pharmacokinetics of the polymers, the nanoparticle size and surface
chemistry/charge can be modified. Size plays a major role in nanoparticle clearance:
nanoparticles less than 10 nm can be filtered out by the kidney, and nanoparticles greater
than 200 nm are typically removed by phagocytosis (36). Hence, nanoparticles of sizes
between these ranges can circulate for a longer period of time and deliver therapeutics.
Changing the surface chemistry by modifying the surface charge or coating with PEG
varies how much the nanoparticle interacts with cells (36). Furthermore, attaching
targeting moieties to the nanoparticles can also increase biodistribution to an organ of
interest (37). This has been used for a wide range of cancer therapeutics and some
targeted towards organs such as the brain and the liver (37).
Liposomes and lipid nanoparticles also have been successful in drug delivery.
These have typically been made from natural phospholipids in order to mimic natural
vesicles and reduce potential toxicity (38). Most liposomes and lipid nanoparticles are
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roughly spherical, but their size can be controlled through differences in synthesis
methodology. Liposomes can also be formed with many layers (38). Liposomes and lipid
nanoparticles can be synthesized through emulsion, extrusion, high pressure thin film
hydration, evaporation, or microfluidic devices (38). Their properties are strongly dictated
by the lipid composition and any additives, including cholesterol, PEGylated lipids, and
polymers (38, 39). Like polymer nanoparticles, size plays a large role in liposomal
clearance, and the effective size ranges are similar to polymeric nanoparticles (38).
Liposomes and lipid nanoparticles can encapsulate both hydrophobic and hydrophilic
drugs, including chemotherapeutics, other small molecules, proteins, peptides, siRNAs,
antisense, oligonucleotides, DNA, mRNA, and other therapeutics (38, 39). Using modified
phospholipids with reactive groups, targeting ligands such as antibodies and small
molecules can be incorporated on the surface to target these therapeutics to specific
organs or to cancerous tissue (38, 39). Liposomal therapies for cancer and rare diseases
are in clinical trials already and some of them are currently used in the clinic (38).
Direct conjugation
Besides formulating into nanoparticles that can deliver in a targeted fashion,
therapeutics can also be attached directly to other types of molecules to improve
pharmacokinetics. Some of these include attaching therapeutics to circulating proteins or
PEG to improve residence time and to targeting ligands to change the biodistribution.
Attaching PEGs and certain polymers to therapeutics can increase their circulation time
as well as prevent immunological recognition or degradation (40). These tactics have
been used to great effect on a wide range of enzyme therapies for rare disease and
cancer in the clinic, as the increased circulation reduces the frequency of dosing required
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to maintain the same amount of enzymatic activity (40). Furthermore, PEGylated versions
of some enzymes of bacterial origin do not provoke the same immune reaction as native
enzyme, allowing their usage in patients with hypersensitivity reactions to the enzyme
(40). PEGylation of certain signaling molecules, such as G-CSF, IFNy, and even insulin
have been used to develop longer-acting forms that still are capable of retaining signaling
capabilities (41). Besides PEGylation, small molecule drug conjugates to carrier proteins
that have long circulation half-lives have also been developed. These primarily involve
albumin, the most abundant protein in serum (42). Not only does conjugation of drug to
albumin improve circulation time, solubility, and tolerability, albumin is preferentially taken
up by tumors, inflamed areas, and the liver (42). These properties have made it a useful
target moiety for therapeutics against diseases such as hepatocellular carcinoma and
rheumatoid arthritis (42).
Therapeutics can also be directly conjugated to a targeting ligand to deliver to
specific locations. These include proteins, antibodies, peptides, aptamers, and even small
molecules. One well-known example of this type of system are antibody-drug conjugates
(ADCs). These are primarily used for cancer therapy, where targeted delivery of
chemotherapeutics to the tumor alone reduces side effects associated with off-target
toxicity (43, 44). Typically, multiple drugs are conjugated to one antibody in order to
deliver a higher level of payload (44). Some ADC systems also include cleavable linkers
that release the drug in the tumor environment (43). ADCs against HER2 and CD30 have
already been approved for use in the clinic (43). Besides ADCs, another area where
conjugates have shown promise is in the delivery of siRNA to cells. One of the most
clinically-advanced siRNA platforms involves using a small molecule ligand (GaINAc)
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directly conjugated to siRNA to deliver to the liver (45). Along with stabilizing chemistries
that make it highly efficacious while retaining a low amount of toxicity, this type of platform
is already in later-stage clinical trials (45). Besides GaINAc, other targeting ligands have
also been attempted for use with similar siRNA systems, including a wide range of integrin
ligands for tumors, CpG ligands for immune cells, and aptamers for prostate cancer (46).
Receptor targeted systems have also been found useful for targeting the brain,
which is naturally protected by the blood-brain barrier. The blood brain barrier is a system
of tight junctions that prevent many types of molecules from entering the brain through
the endothelium (47). However, conjugates of therapeutics to antibodies against the
insulin receptor or transferrin receptor have allowed for delivery of these therapeutics into
the brain parenchyma at rates competitive with small molecule drugs (48). These types
of conjugates are in trials for lysosomal storage diseases, which are rare inherited
disorders of lysosomal processing that lead to accumulation of waste products in the
lysosome (48, 49). Enzyme replacement therapy has been successful in improving the
quality of life for a wide range of patients, but the inability of these enzymes to cross the
blood brain barrier prevents their use in patients with cognitive involvement (49). Besides
antibodies, small molecules have also been used to deliver therapeutics to the brain:
siRNA-sertraline conjugates administered intranasally have been shown to induce
knockdown in the brain (50). For brain tumors, proteins such as chlorotoxin have also
demonstrated efficacy in taking molecules such as chemotherapeutics and diagnostic
agents across the blood brain tumor barrier (51). Fluorescently-la belled chlorotoxin is in
clinical trials for glioblastoma as a surgical adjunct to help surgeons visualize the tumor
margin (52).
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Local delivery
Local delivery is one of the mainstays of modern drug delivery. Besides injections,
there have been a wide variety of methods developed to deliver drugs locally, including
microneedles, patches, and implantable devices such as pumps and polymer release
systems (53). Many such systems rely on using proximal diffusion gradients to release a
drug into its immediate environment in order to minimize the amount systematically in the
bloodstream. These systems are already in use in the clinic, mostly for cancer
therapeutics (53). An example of this is the Gliadel wafer for glioblastoma, which is
situated in the tumor site after resection and releases chemotherapeutics that suppress
any leftover tumors (53). This allows local concentrations of the drug to be highest at the
tumor site and lower elsewhere in the body where toxicity could occur.
Strategies for temporal control of therapeutics
Another aspect of drug delivery is changing the kinetics of delivery. Traditionally,
this has been done to slow down release to reduce administration frequency, but recently,
other methods have been developed to modulate the profile. For orally-delivered drugs,
there have been a variety of systems developed to decrease the rate of passage and
prolong the release of drug. Local delivery systems have also been deployed with
polymers that either degrade or swell over time, slowly releasing molecules. Recently,
newer methods of controlled release have been developed that are responsive to external
stimuli.
Gastrointestinal systems
Oral delivery of pharmaceuticals has been the mainstay of the pharmaceutical
industry. However, in order to maintain consistent concentrations of therapeutics,
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frequent dosing may be needed. In order to overcome this limitation, several types of
systems have been invented to increase the transit time through the GI tract and lengthen
dosing (54, 55). Some of these use mucoadhesive coatings, which are generally made
from polymers that interact with intestinal mucus (54). These interactions can be through
hydrogen bonds or van der Waals forces, although some may actually interact through
binding with receptors as well (54). Mucoadhesive coatings significant slow transit time
and allows for hours of drug release (54).
Other systems use physical properties of the stomach to keep a drug delivery
device in the stomach for a prolonged period of time. These include systems that swell in
acidic conditions to sizes that prevent the device from leaving the stomach (54). This
allows the drug to be slowly released until the device is eroded. Floating systems have
also been developed that float in the stomach and thereby avoid transport out of the
stomach (55). The floatation device can be designed to have low density, but other
systems have been designed to self-inflate upon hitting the acidic environment of the
stomach by generating carbon dioxide gas (55). Such systems are able to stay afloat and
continue to release drug on the order of days (55).
Passive local systems
Polymeric systems have been widely used to change the release profile of a wide
range of therapeutics. They have been fashioned in a wide range of shapes and sizes,
ranging from microparticles and gels to films and rods. Microparticle drug release systems
were developed to create injectable depots for long-lasting release of drugs using
polymers that slowly degrade (56). Besides the polymer, the shape and size of these
materials also play a large role in how they degrade and release drug (56). These
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technologies are already clinical stage, and have been used to encapsulate a wide range
of drugs, ranging from luteinizing hormone releasing hormone to cancer drugs such as
doxorubicin and paclitaxel (56). Although most microparticle systems are injected, some
can also be formulated as inhalable systems in order to deliver drugs to the lung (57).
These have been used in the clinic to treat lung cancer, lung transplant rejection, and
cystic fibrosis(57). Currently, these formulations allow drugs to be released at a fairly
consistent rate for months (56).
Besides microparticles, a wide range of other types of local release systems have
also been developed. Many of these are implantable systems with a reservoir of drug held
within. Devices such as osmotic pumps, microchannel systems, membrane-base
devices, microneedles, and others have been developed that hold the drug within the
system (53, 58). Such systems can be implanted or affixed to the skin in easily-accessible
locations and release drugs systemically for years in certain cases (58). These systems
have primarily been used for small-molecule drugs (58). Some of the ones in the clinic
currently are devices that release contraceptives, other hormones, and cancer drugs (58).
A wide range of devices have also been developed for ophthalmic use, primarily to
release drugs for glaucoma and retinopathies (58). Drug eluting stents have also been
developed that release drugs and prevent further narrowing of the blood vessel, thereby
increasing the useful life of the stent (58).
Responsive systems
Most systems for sustained release function due to diffusion. However, newer
methods of delivery have been developed that are capable of releasing drugs in response
to certain external stimuli. Many of these responsive systems have been engineered
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using chemistry that allows them to modulate release based upon presence of certain
stimuli. One example of this type of system are glucose-responsive insulin delivery
systems, which reduce the risk of hypoglycemia in diabetics who use insulin (59). These
have typically been designed using phenylboronic acid or concanavalin A, which both
bind to glucose (59). High glucose concentrations then change the conformation of a
larger nanostructure and either lead to release of insulin or activation of an inactive form
of insulin (59).
Electronically controlled systems have been developed that allow for release of
drug upon reception of a signal (60). These microelectromechanical systems are
fabricated with process similar to those used in the semiconductor industry, allowing them
to be made to a very small size (60). Up to thousands of nanoliter-sized doses of drug
are stabilized within individual wells in these systems, and thus can be released years
after implantation upon appropriate signaling through electrical destruction of a cap
material (60). Such devices are currently in clinical trials for applications including
chemotherapy and osteoporosis (60).
Responsive systems have also been developed using biological circuitry to control
delivery. Because cells already are capable of controlling secretion in response to
stimulus, using them to manufacture or deliver drugs helps ensure that drugs are
delivered to the right location at the right time. However, introducing other cells in the
body can lead to immune attack and destruction, so methods are needed in order to make
these systems useful (61). As an example, new biomaterials have been developed that
are capable of shielding cells from the immune system (61). These materials have been
used to encapsulate islet cells that naturally secrete insulin in response to glucose (61).
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Similar systems have also been developed for using hepatocytes in the case of liver
failure (62).
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Chapter 2: Vaccine kinetics
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Overview
Subunit vaccines based on recombinant protein antigens combined with adjuvants can
safely elicit protective humoral immune responses in humans, and they have become a
cornerstone of modern public health (1, 2). Recent advances in structure-based vaccine
design (3, 4) and progress in the development of adjuvants that are safe and effective for
prophylactic vaccines (5) have helped drive the field. However, several challenges
remain: A number of protein vaccines, such as candidate vaccines against HIV and
malaria, have tended to elicit short-lived immunity (6, 7). In HIV, broadly neutralizing
antibodies (BNAbs) isolated from infected patients are generally characterized by high
degrees of somatic hypermutation (SHM) (8), but methods to generate such highly
mutated antibodies by vaccination remain unknown. SHM occurs in germinal centers
(GCs) within lymphoid organs, and data from animal models demonstrate a critical role
for follicular helper T-cells in the induction of GCs and promotion of affinity maturation (9,
10). To date, methods to promote Tfh generation and long-lived germinal centers during
vaccination remain unclear (11-15). Much attention has focused on the use of adjuvants
to promote affinity maturation, but it remains unclear if adjuvants alone can provide the
necessary immunological driving forces for promoting extensive affinity maturation (16).
During acute infections, which often provoke robust germinal center responses and
durable humoral immunity, microorganism replication typically occurs over the course of
one to several weeks (17-19). During this time, recognition of molecular danger signals
contained within the pathogen sustains stimulation of the innate immune system, and a
continuous supply of antigen is provided to the adaptive immune system. In contrast to
these patterns of antigen and inflammatory cues during infection, typical subunit vaccines
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show much more rapid clearance following injection. During a primary immune response,
parenterally-injected proteins are detected in lymph nodes within minutes to a few hours,
but are largely flushed away within 1-2 days (12, 20). Adjuvants such as alum and MF59
are believed to act as antigen depots altering these kinetics, but biodistribution studies
suggest that clearance of antigen from injection sites and lymph nodes is often nearly
indistinguishable for soluble vs. alum-adsorbed or MF59-adjuvanted antigens (21-23). As
such, the impact of subunit vaccine kinetics on the humoral immune response remains
poorly understood. Given that germinal centers peak multiple weeks after antigen
exposure, it is reasonable to postulate that antigen kinetics may have a profound impact
on the magnitude and quality of the germinal center response and long-term humoral
immunity.
Here we explored the effects of systematically varied temporal dosing patterns on the
humoral immune response to model HIV subunit vaccines consisting of recombinant CD4
binding site-presenting gp120 monomer (24, 25) or SOSIP native-like HIV Env trimer
proteins (26-28). We find that certain extended-duration dosing profiles increased the
strength of the humoral response, with exponentially-increasing patterns providing the
greatest enhancement. Guided by a computational model of the effects of vaccine
kinetics on the germinal center response, we found that exponential-increasing dosing
kinetics promoted capture and retention of the antigen in lymph nodes, leading to
increased germinal center B-cell expansion, plasma cell generation, and Tfh cell
numbers.
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Exponentially-increasing dosing profiles during priming durably increase the
production of antigen-specific IgG
We hypothesized that extended exposure to antigen and adjuvant, better mimicking the
kinetics of live infections, would augment the response to vaccination. As a model
vaccine, we employed a previously-described gp120 "stripped core" antigen containing
the CD4 binding site (24, 25), which was mixed with monophosphoryl lipid A (MPLA) as
a clinically-relevant adjuvant (29). We first evaluated the effect of altering vaccination
kinetics by extending the dosing of the prime over 1 week. Groups of mice were
immunized with either a conventional bolus injection on day 0, or 7 daily injections over 1
week testing three concepts: exponentially-increasing (exp-inc), exponentially-
decreasing (exp-dec), or constant dosing, where the summed total dose of antigen and
adjuvant was kept the same in all groups (Figure 2.1A and Table 2.1). All groups received
a boost as a single bolus injection at day 21. Following priming, exp-inc and constant
dosing profiles elicited strikingly higher IgG responses by day 14 compared to bolus
immunization, with anti-gp120 Ab concentrations 14- and -8-fold higher (p < 0.001)
respectively than bolus injection at day 14, roughly equivalent to the titers achieved by
traditional bolus immunization after the boost (Figure 2.1B-C). By contrast, an exp-dec
dosing pattern elicited titers post-prime that were indistinguishable from the bolus control.
Following the boost administered at day 21, animals that received an exp-inc prime
continued to show higher anti-gp120 Ab levels, which were 2.7 times greater (average
over time) than the bolus-primed group (Figure 2.1C, p < 0.001). This effect was durable,
lasting 150 days. By contrast, the constant-dosing prime elicited Ab levels only 1.6 times
higher than bolus injection (p = 0.040) and the exp-dec prime was not significantly
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different from bolus prime. Thus, certain extended vaccine kinetic profiles, especially in
an increasing dosing pattern, enhanced the long-term concentration of antigen-specific
IgG produced.
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Figure 2.1. Exponentially-increasing dosing schedules during priming durably
increase antigen-specific IgG production relative to traditional bolus immunization.
Groups of C57BL/6 mice (n = 5/group) were immunized with 5 pg gp120 mixed with 25
pg MPLA according to the dosing schedules shown in (A), followed by a single bolus
booster injection of 5 pg gp120 + 25 pg MPLA on day 21. (B) Fold change in antibody
concentration on day 14 post-prime relative to bolus injection. *, p <0.05; ***, p <0.0001
compared to bolus injection determined by ANOVA with Dunnett's test post hoc using
bolus injection as the control. Shown are means s.e.m. (C) Total serum anti-gp120
IgG as measured by ELISA. *, statistically different from boost d21 group as determined
by 2-way ANOVA with Dunnett's post hoc test using bolus injection as the control. Data
is representative of two independent experiments.
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Table 2.1. Vaccine doses for each kinetic immunization pattern.
Dosing Exponential Exponential Constant Bolus
Profile: increasing decreasing
Day gp120 MPLA gp120 MPLA gp120 MPLA gp120 MPLA
(ug) (ug) (ug) (ug) (ug) (ug) (ug) (ug)
0 0.010 0.050 3.089 15.446 0.714 3.571 5 25
1 0.026 0.130 1.188~ 5.941 0.714 3.571 - -
2 0.068 0.338 0.457 2.285 0.714 3.571 - -
3 0.176 0.879 0.176 0.879 0.714 3.571
4 0.457 2.285 0.068 0.338 0.714 3.571 - -
5 1.188 5941 0.026 0.130 0.714 3.571 -
6 3.089 15.446 0.010 0.050 0.714 3.571 - -
Extended dosing profiles over two weeks maximize antibody titers
We hypothesized that dosing over a 1 week period may be suboptimal, given the more
prolonged kinetics of germinal centers and the kinetics of many acute infections. As exp-
inc dosing resulted in elevated antibody titers, we next tested how the duration of this
dosing pattern influenced the humoral response. We compared exp-inc dosing profiles
'administered over 7, 14, or 21 days, keeping the total number of injections (7) and total
dose constant. For each pattern, the bolus boost was given 14 days after the last priming
injection (Figure 2.2A and Figure 2.3A). In order to account for the effect of a later boost,
we also introduced a second control with single dose prime and a boost at day 28. As
seen in Figure 2.2B, extending the dosing course from 7 to 14 days increased the
magnitude of the antibody response, with the 2-week exp-inc dosing pattern eliciting -48-
fold higher concentrations of gp120-specific antibodies than the corresponding bolus
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prime group by day 21 (p < 0.001, Figure 2.2B). Further extending the exp-inc dosing
profile from 14 days to 21 days led to a slightly weaker humoral response than the 2-week
profile (Figure 2.3). Post-boost, 1-week and 2-week exp-inc dosing elicited sustained
gp120-specific IgG levels that were 3.6-fold (p < 0.001) and 6.6-fold higher (p < 0.001)
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than their equivalently-timed bolus prime/boost controls (Figure 2.2C).
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Figure 2.2 Exponentially-increasing dosing profiles extended over 2 weeks with an
exponentially-increasing boost enhance the humoral response.
Groups of C57BL/6 mice were immunized with 5 [tg gp120 + 25 ptg MPLA following the dosing
schedules shown in (A) and (D). (B) Fold change in antibody concentration on day 21 post-prime
relative to bolus injection. p was determined by unpaired Mann-Whitney test. (C) Total serum
anti-gp 120 IgG (n = 10/group) as measured by ELISA. *, statistically different from boost d21
group as determined by 2-way ANOVA with Dunnett's post-hoc test using bolus injection as the
control. (E) Fold change in antibody concentration on day 49 (post-boost) relative to bolus
injection. *, p <0.05 determined by Kruskal-Wallis test with Dunn's multiple comparison's test.
(F) Total serum IgG (n = 5/group) measured by ELISA. *, statistically different from boost d21
group as determined by 2-way ANOVA with Dunnett's post-hoc test using bolus injection as the
control. (G) Mice were immunized either with gp120 plus MPLA following schedules shown in
(D) or with gp 120 formulated in 100 tg alum (aluminum phosphate, prime day 0, boost day 28).
Serum was collected at day 49 and anti-gp120 isotype titers were analyzed by ELISA. *,
statistically different from boost d28 group as determined by 2-way ANOVA with Dunnett's
post-hoc test using bolus injection as the control. (H) ELISA for binding to gp120 for day 49 sera
was performed in the presence of competing broadly-neutralizing antibody VRCO 1. Shown is
ELISA optical density as a percentage of uncompeted signal. p was calculated by unpaired
Mann-Whitney test. All values shown are mean s.e.m. Data are representative of experiments
done twice (A-C) or once (D-H), using at least 5 mice per group.
To determine the relative importance of an increasing dosing profile on the prime vs.
boost response, we compared exp-inc dosing profiles administered only during the prime,
only during the boost, or during both prime and boost (Figure 2.2D). Incorporation of an
exp-inc dosing profile for both the prime and boost resulted in significantly higher serum
Ab concentrations than either exp-inc prime/bolus boost or bolus prime/exp-inc boost
regimens (Figure 2.2E-F). To evaluate the impact of extended dosing on class switching,
we analyzed titers of different Ab isotypes induced. Exp-inc dosing substantially increased
the titers of multiple Ig isotypes, including IgG1, IgG3, and IgG2a that was near
background following traditional bolus immunization (Figure 2.2G). We also compared
exp-inc vaccination to traditional bolus vaccination using alum as the most common
clinical adjuvant, which has been proposed to provide a depot effect with some antigens
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(30). As shown in Figure 2.4, alum provided comparable antibody responses to bolus
vaccination using MPLA as adjuvant (p = 0.88), but was much inferior to exp-inc dosing
of the vaccine, and also elicited almost exclusively IgG1 titers (p = 0.038, Figure 2.2G).
Finally, we tested the capacity of vaccine-elicited antibodies to compete with the BNAb
VRC01 for binding to the gp120 antigen by ELISA, exp-inc vaccine dosing increased the
proportion of antibodies induced that blocked VRC01 binding (Figure 2.2H).
Altogether, these results indicate that for a given total quantity of antigen and adjuvant,
extended vaccine kinetics obtained by administering the vaccine over at least 2 weeks in
increasing doses is capable of durably increasing total output serum concentrations of
elicited antigen-specific IgG by more than 7-fold, elevating the production of multiple
isotypes of Ab.
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Figure 2.3. Extending exponential increasing dosing over 3 weeks results in lower
antibody titers.
Groups of C57BL/6 mice (n = 5/group) were immunized with 5 pg gp120 + 25 pg MPLA
following the dosing schedules shown in (A). (B) Fold change in antibody concentration
on day 43 (post-boost) relative to bolus prime and boost injections. p value determined
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by unpaired Mann-Whitney test. Data is representative of two i
using 5 mice per group.
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Figure 2.4. Exp-inc vaccine dosing elicits substantially higher antibody titers than
vaccination with alum.
Groups of C57BL/6 mice (n = 5/group) were immunized with 5 pg gp120 + 25 pg MPLA
following the dosing schedules shown in Fig. 2D. The alum group received bolus
immunization with 5 pg gp120 and 50 pg alum (aluminum phosphate) following the
same schedule as the bolus "Boost d28". Shown are serum gpl20-specific IgG titers vs.
time. *, statistically different from boost d28 group as determined by 2-way ANOVA with
Dunnett's post-hoc test using bolus injection as the control.
A computational model of the germinal center response predicts antibody-based
feedback governs the response to extended dosing vaccines
In a traditional bolus immunization, the half-life of the antigen present in lymph nodes is
shorter than the time scale over which germinal center (GC) reactions start producing
higher affinity IgG antibodies relative to the initial IgM response (12, 20). Thus, most
antigen displayed on follicular dendritic cells (FDCs) is in the form of immune complexes
(IC) of antigen with weakly-bound IgM antibodies (31, 32); this may lead to a sub-optimal
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level of antigen concentration on FDCs. We hypothesized that extended vaccine dosing
may better match the timescale of antigen availability to the kinetics of the GC reaction
compared to bolus immunization, leading to more ICs formed with newly-evolved higher
affinity antibodies, thereby promoting more prolonged retention on FDCs. To explore
whether this feedback mechanism alone can account for the significant effect of extended
dosing profiles observed experimentally, we constructed a coarse-grained computational
model with a minimal number of parameters. The goal of the model was to test whether
our hypothesis could provide an explanation for the data, and if so, to subject it to
experimental tests. The model particularly focuses on antigen transport, the germinal
center (GC) reaction, and antibody production by plasma cells in a lymph node (Figure
2.5A). It makes the following assumptions: (1) As a simplified approximation of
experimental observations of soluble antigen transport following injection, we assume that
antigen arrives at the lymph node immediately following immunization, and free antigen
in the lymph node clears exponentially over time with a half-life of approximately 17 hr
(20, 33). Natural IgM initiates the immune response and captures antigen arriving in the
lymph node with a low affinity (32). (2) B-cells class-switch only to IgG and not to other Ig
subclasses after the GC reaction ensues. (3) The onset of IgG production occurs 6 days
after the initial antigen injection, reflecting the observation that it takes a few days for GC
reactions to occur before class switching initiates (34, 35). (4) The GC B-cell population
size is assumed to be constant during the GC reaction. While this is incorrect, qualitative
results emerging from models of evolutionary processes that make this approximation are
often accurate (36). (5) The formation of immune complexes (ICs) is the rate-limiting step
in antigen presentation to GC B-cells; i.e., the model assumes that transport of immune
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complexes to FDCs is relatively fast. (6) 10% of selected B cells differentiate to plasma
cells (24). (7) IgG affinity evolves linearly, and increases by 1 00-fold by the end of the GC
reaction (24). Based on these assumptions, four key reactions summarize the model
(Figure 2.5B). During the early phase of the immune response, free antigen is captured
by IgM at a slow rate (proxy for affinity), P3 (Figure 2.5B, Reaction 1). B-cells bind to ICs
in GCs with an increasing rate #2 (proxy for affinity) as a function of time, and become
plasma cells (Figure 2.5B, Reaction 2), which ultimately leads to production of IgG (Figure
2.5B, Reaction 3). Because this is a coarse-grained model, we consider only the average
affinity of IgGs, although in reality there is a heterogeneous distribution. Plasma cells
derived from the GC reaction produce antibodies at a rate k (Figure 2.5B, Reaction 3),
and the resulting higher affinity antibodies capture antigen (Figure 2.5B, Reaction 4) at a
rate 82. Parameter values were taken from the literature (Table 2.2) when available,
except for k, which is the number of antibodies produced by each plasma cell per day.
Non-linear regression fitting of the model antibody output to IgG concentrations measured
experimentally at days 7 and 14 following gp120 immunizations was performed to
determine the best value of k. This yielded a value for k of 2.56x1 06 antibodies per plasma
cell per day, which in rough agreement with the reported rate of ~10 7 IgG molecules
secreted by a single plasma cell per day (37).
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Figure 2.5. A computational model of the germinal center response predicts
enhanced immune complex formation and IgG production by extended-
dosing/increasing vaccination profiles.
(A) Schematic of components of antigen transport, GC reaction and antibody production
model. (B) Four reactions of the model including antigen capture by ICs at initial and
later stages of the immune response, coarse-grained germinal center reaction and
antibody production. CB, concentration of germinal center B cells; CAg, concentration of
free Ag; Cic, concentration of ICs; Cigm, concentration of lgM; CIgG, concentration of IgG;
Cpc, concentration of plasma cells. (C) Kinetic profile of free antigen in lymph nodes
predicted by the model with fitted k. (2.56 * 106 antibodies/plasma cell per day) (D)
Kinetic profiles of IC, IgM, IgG, Plasma cells and Total antigen in lymph node (free Ag+
IC) predicted by the model. See also Germinal center model calculations in Materials
and Methods and Equation S1. for mathematical representation of the model.
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Table 2.2. Parameter values and initial conditions
Parameter Value
BAg, Free antigen decay rate 1 /day
DAb, IgG decay rate 0.0233/day
Dic, FDC presented IC decay 0.0233/day
rate
Dpc, Plasma cell death rate 0.03/day
P1, Basal level on-rate 103/(M*S)
y, GCB cell concentration 1.44x1 02 M
Initial conditions
CAg(t=O), CIC(t=O), CIgM(t=O),
CIgG(t=O), CPC(t=O)
10 4Bcells 1 100GCs 2
GC lymph-node
imol X )
6.02x10 2 3 cells luL
Value
[0,0,10 ,','OO]
used in the model.
Reference
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1.
2.
3.
63
64
65
66
67
Reference
68
Initial concentration of natural IgM was taken to be
proportional to the level of IgG measured at day 7
multiplied by the ratio of IgG/lgM binding to SAg-
gpl20 (1:1) before immunization, to reflect the IgM
level before immunization
Using these parameters, we modeled the GC reaction, immune complex formation, and
IgG production for each of the 1-week vaccine dosing schedules studied experimentally
in Figure 2.1 (Figure 2.5C). As shown in Figure 2.5D, the model predicts that the
hierarchy of antibody production among the different dosing schemes mirrors the
hierarchy of IC concentrations. Exp-inc dosing produces the highest level of immune
complex formation and thus the highest level of antibody output. The exp-inc dosing
profile also leads to increased GC activity and increased numbers of plasma cells. By
contrast, the calculations suggest that IC accumulation using the exp-dec dosing scheme
is very low and similar to that from a bolus immunization (Figure 2.5D), consistent with
the experimental finding that antibody production in these two cases was similar. A key
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prediction of the model is that total antigen in lymph nodes quickly decays 24 hr after the
bolus immunization, while antigen is retained at high levels for many days at the end of
the exp-inc dosing schedule (Figure 2.5D). Thus, a simple model of the GC reaction
focused on the impact of early antibody evolution on antigen capture in ICs reproduces
the qualitative results seen in our experiments, and suggests that a key mechanism of
action is enhanced capture/retention of antigen in lymph nodes in the exp-inc dosing
profiles.
Exponential-increasing dosing results in prolonged antigen retention in lymph
nodes and enhanced germinal center formation
Motivated by the modeling predictions, we performed a series of experiments using
infrared dye-labeled gp120 to track the amount of antigen retained in draining lymph
nodes over time, and evaluated GC induction following priming with bolus immunization
or exponentially-increasing dosing. Groups of mice were immunized with labeled gp120
and MPLA, then serially sacrificed to recover tissues for digestion and quantification of
total gp120 fluorescence in the draining inguinal LNs at selected time points. Lymph
nodes were analyzed at 24 and 72 hr following bolus injection, or 24 and 72 hr after the
final injection in a 2-week exp-inc dosing regimen Figure 2.6A). Following bolus
immunization, antigen was detected in the LNs at 24 hr, but quickly decayed thereafter
(Figure 2.6B). By contrast, at the end of the exp-inc dosing regimen, antigen remained at
high, approximately constant levels for at least 3 days. To determine the anatomical
localization of retained antigen, we repeated this experiment using phycoerythrin (PE) as
an intrinsically fluorescent model protein antigen, vaccinating with a bolus or exp-inc
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dosing regimen. Twenty-four hr after bolus immunization, little or no antigen could be
detected on FDCs or any other location in lymph nodes, while 24 hr after the final injection
in the exp-inc regimen, substantial amounts of PE were detected lining the FDC network
(Figure 2.6C). Thus, exp-inc dosing enhanced antigen retention in lymph nodes at the
end of the injection schedule compared to bolus vaccination, with preferential retention
on FDCs, as predicted by the computational model of the GC reaction.
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Figure 2.6. Exponential-increasing vaccine dosing leads to enhanced antigen
capture and retention in draining lymph nodes.
Groups of albino C57BL/6 mice received s.c. injections of 5 pg of lRDye800-labeled
gp12O plus 25 pg of MPLA. Relative amounts of gp12O in the lymph nodes were
quantified by fluorescence. (A) Dosing and sampling profiles used in this experiment.
(B) Fluorescence detected from lymph nodes ex vivo (n = 4/group) at 24 or 72 hours
post last injection. p value was calculated by unpaired Mann-Whitney test. Data is
representative of two independent experiments. (C) Groups of C57B116 mice
(n=2/group) were vaccinated with 5 pg phycoerythrin and 25 pg MPLA by bolus or exp-
50
inc dosing following the schedule in (A), followed by collection of lymph nodes for
imaging at 72 hr after bolus or after last injection of 2wk exp-inc dosing. FDC networks
were labeled in situ by i.p. injection of anti-CD21/35 antibody 16 h prior to tissue
collection. Collected tissues were clarified and imaged intact by confocal microscopy;
shown are maximum intensity projections from z-stacks through FDC clusters. Scale
bar 80 pm.
We next analyzed B-cell populations in the draining inguinal lymph nodes of mice
receiving bolus vs. 2-week exp-inc vaccine dosing regimens (Figure 2.7A). Germinal
center B-cells were tracked over time, and plasmablasts were compared by flow
cytometry on days 7 and 13 for both regimens. Significant numbers of GC B-cells did not
develop following bolus immunization until day 13 and the GCs contracted by day 21
(Figure 2.7B-C). Exp-inc-vaccinated mice showed germinal center responses over a
similar timeframe, but GC B-cell numbers escalated dramatically between day 7 and 13,
reaching 3.7-fold higher peak levels of GC B-cells (p = 0.040 for 2wk exp-inc d13 vs Bolus
d13, Figure 2.7B-C). Notably, exponential dosing led to overall greatly increased cell
numbers in lymph nodes at these peak GC time points. Adjuvant-only and antigen-only
controls indicated that this germinal center response was largely antigen-specific but
dependent on the presence of adjuvant (Figure 2.7C). Exp-inc vaccination also
stimulated a massive expansion of plasma cells on day 13, which was not observed at
any time point for traditional bolus immunization (p < 0.0001, Figure 2.7D). B-cell
activation in the draining LNs at 24 hr after the final injection of the exp-inc dosing regimen
was similar to 24 hr post bolus injection (Figure 2.7E). Thus, an escalating pattern of
vaccine dosing amplified the germinal center response and altered B-cell differentiation
patterns in the lymph node.
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Figure 2.7. Exponential-increasing vaccine dosing promotes germinal center B-cell
differentiation.
C57BL/6 mice were immunized with either 5 pg gp120 and 25 pg MPLA, MPLA only or
gp120 only, following the dosing schemes depicted in (A). (B) Lymph node sections
were stained for B-cells (B220, blue) and GL7 (pink), and analyzed by confocal
microscopy (10x magnification). (C-E) Draining LNs were collected at the indicated time
points, and cell suspensions were analyzed by flow cytometry to detect germinal center
B cells (C, GL7+PNA*lgD'*w), plasmablasts (D, CD138'B220-) and activated B cells (E,
B220+MHCIl*CD86*). Representative flow cytometry plots (left) and cell counts (right)
are shown. *, p <0.05; **, p <0.01, ***, p <0.001 determined by Kruskal-Wallis test with
Dunn's multiple comparison's test. Error bars are s.e.m. Data is representative of four
independent experiments.
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True continuous antigen exposure elicits increased germinal center and serum
antibody responses
Because we experimentally prolonged vaccine dosing through repeated injections, a
question that remained was whether similar vaccine results would be obtained in the
setting of true continuous antigen exposure. To answer this question, a series of
experiments were performed using mini osmotic pumps, non-mechanical delivery devices
that can release a material continuously over a specific period of weeks in vivo when
implanted subcutaneously. Mice were immunized with osmotic pumps containing native-
like BG505 SOSIP HIV Env trimers (26-28) admixed with an ISCOMs-type adjuvant, and
CD4' T-cell, B-cell, and antibody responses were assessed. As shown in Figure 2.8A,
we compared traditional bolus vaccination with SOSIP trimer and ISCOMATRIX to
immunizations where osmotic pumps were implanted for release of vaccine over 1 week,
or immunizations using pumps releasing vaccine for 2 weeks. Motivated by our results
that suggest the key feature of the escalating dosing pattern is the availability of antigen
at the end of the dosing schedule, we administered a bolus injection at the end of each
pump lifespan (day 7 and day 14, for the 1 week and 2 week pumps, respectively) to
provide a high dose of antigen at the end of the dosing pattern. Animals in each group
were boosted with the same regimens after 8 weeks and 19 weeks. We evaluated GC B-
cell and Tfh cell numbers 4 weeks after the final immunization. Sustained immunogen
delivery using the osmotic pumps increased the frequency and absolute number of
germinal center Tfh cells (CXCR5hi PD-1h, Figure 2.8B) and overall Tfh cells (Figure 2.8C)
in the draining lymph nodes. The greatest GC Tfh increase (-3 fold) was observed for
pumps providing 2 weeks of vaccine release. Total numbers of Tfh cells (CXCR5+BTLAhi)
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Figure 2.8. Continuous vaccine release via osmotic minipumps leads to increased Tfih and
GC B cells and amplified antibody responses.
(A-D) C57BL/6 mice were immunized with 20pjg HIV- 1 Env BG505 SOSIP trimer via
conventional bolus injection, 'Bolus'. A second group, '7d minipump', was immunized with 7-
day minipumps continuously releasing HIV- 1 Env BG505 SOSIP trimers (50 pg, 7.1 pg/day),
supplemented with 20 pg BG505 SOSIP trimer via bolus injection at the end of each 7d pump
immunization. A third group, '14d minipump', was immunized with 14-day minipumps
continuously releasing HIV- 1 Env BG505 SOSIP trimers (100 pg, 7.1 pg/day), supplemented
with 20pg BG505 SOSIP trimer via bolus injection at the end of each 7d pump immunization. A
course of three immunizations was used, paralleling a human vaccine schedule. (B-D) Draining
LNs were collected at wk 24, four weeks after the final immunization, and lymphocytes were
analyzed by flow cytometry to detected (B) GC Tfh cells (CXCR5+PD-lhi), (C) Tfh cells(CXCR5+BTLAhI), and (D) germinal center B cells (FAShIGL7hi). Representative flow cytometry
plots (left) and cell counts (right) are shown. (E-F) B6 mice were immunized with conventional
20pg bolus injections of HIV-1 Env BG505 SOSIP trimers ('Bolus'). A second group was
immunized with 14-day minipumps continuously releasing HIV-1 Env BG505 SOSIP trimers(1.4 pg/day), supplemented with 20 pg BG505 SOSIP trimer via bolus injection at the end of the
14d pump immunization ('pump'). ISCOMATRIX adjuvant was used in each case. (E) Env
trimer binding IgG was quantified by ELISA. Dotted line indicates time of second immunization
(wk8). (F) ELISA for off-target V3 loop antibodies. Data are representative of two independent
experiments. *, p <0.05; **, p <0.01. Error bars are s.e.m.
measured by flow cytometry were also increased by osmotic pump-based sustained
vaccine kinetics, with 2 week osmotic pumps eliciting the greatest increase in total Tfh
numbers compared to bolus immunizations (Figure 2.8C). Overall numbers of GC B-cells
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were elevated -3-fold by the 2-week extended dosing osmotic pump regimen (Figure
2.8D), consistent with the knowledge that GC B cell numbers closely correlate with the
availability of GC Tfh cells. No response was observed in animals receiving adjuvant
alone (Figure 2.9).
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Figure 2.9. Adjuvant alone does not induce germinal center responses.
(A) C57BL/6 mice were immunized with 0.2 pig ISCOMs alone or with 10 pig BG505 SOSIP
trimers and 0.2 ptg ISCOMs at Weeks 0, 6, and 20. Germinal center responses in draining lymph
nodes were analyzed at Week 22. (B) Flow plots and (C) graphs of GC Tfh cells (CXCR5+PD-
lh1), Tfh cells (CXCR5+BTLAhi), and germinal center B cells (FAShiGL7hi) in draining lymph
nodes of mice immunized with adjuvant alone or with trimer and adjuvant.
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Native-like SOSIP Env trimers generally elicit very low serum antibody responses after
primary immunization (38, 39), which is a common feature of many protein immunogens.
In contrast, provision of immunogen by extended in vivo release elicited significant anti-
trimer IgG responses after the first immunization (Figure 2.8E). These enhancements
translated to a 15-fold increase in total SOSIP-specific IgG titers in the serum after booster
immunization (P=0.0062, Figure 2.8E). Additionally, consistent with our previous study
(39), bolus immunization led to a preponderance of antibodies directed against the V3
loop not exposed on the intact trimer, suggesting some degree of active degradation of
the immunogen in vivo (Figure 2.8F). These non-neutralizing V3-specific responses were
not detected in the osmotic pump-immunized animals (Figure 2.8F), demonstrating that
the osmotic pumps both provide robust immunological response benefits by altering the
antigen dose kinetics and protect the immunogen structure. Thus, consistent with our
findings from dosing profiles achieved by repeated injections, extended vaccine dosing
with osmotic pumps led to increased antibody titers and GC development.
Discussion
The majority of licensed vaccines are thought to protect through the induction of long-
lived neutralizing antibody responses (40). Methods to enhance humoral immunity and
particularly to promote the germinal center reaction where antibody affinity maturation
occurs are of great interest for improved vaccines, and may be especially important for
the development of a successful HIV vaccine (41-43). Strategies to influence the B-cell
response include the selection of appropriate adjuvants (5), use of multiple immunogens
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to "steer" antibody responses (44, 45), and control over the dose and timing of antigen
and adjuvant exposure through the method of vaccine delivery (46). Recent unexpected
findings with HIV Env protein vaccines in non-human primates demonstrating that a
variety of clinically-relevant adjuvants fail to promote affinity maturation to degrees greater
than injection of protein alone indicate that adjuvants alone may not be capable of
inducing optimal antibody responses (16).
Here we focused on the temporal profile of vaccination and its impact on the humoral
response. Generating three basic temporal patterns of vaccine exposure, we found that
administering antigen in increasing doses with time led to humoral responses that were
significantly greater than constant-dosing or decaying-dosing profiles. Exponential-
increasing dosing over 2 weeks at both prime and boost durably increased antibody titers
19-fold relative to traditional bolus immunizations. A computational model suggested that
extended antigen dosing profiles lead to better antigen capture in the germinal center
because of the delayed nature of IgG IC formation. These predictions were borne out by
experimental analyses demonstrating that exponential-increasing vaccine kinetics led to
prolonged antigen retention in lymph nodes and enhanced germinal center induction.
A number of studies have sought to enhance immune responses through the use of
controlled-release devices to sustain vaccine exposure over prolonged periods, but these
efforts have largely focused on the notion of replacing repeated injections with constant
continuous exposure over 1 or more months, and mechanisms underlying the response
to such sustained release formulations have not been explored (47-50). We were inspired
by the previous work of Johansen et al. (51), who demonstrated that T-cell responses to
peptide vaccination are substantially enhanced by immunizing in an increasing dosing
57
pattern. Here we show that such vaccine kinetics are also highly favorable for the
antibody response, through the interplay of antibody production and B-cell stimulation in
germinal centers. The strong influence of vaccine kinetics on the antibody response is
likely an evolved mechanism optimizing B-cell activation in the face of replicating
pathogens. Antigen load and inflammation during acute infections follow similar kinetic
patterns as the exponential-increasing dosages that elicited optimal antibody titers and
GC induction in these simple protein vaccinations. Furthermore, GCs can be active for
weeks or months, and thus it is logical that the availability of vaccine antigen at later time
points in that process can be an important limiting factor for the quantity and quality of the
memory B cells and plasma cells produced by the GCs.
Though we focused our studies here on fixed doses of antigen/adjuvant, the total dose of
the vaccine will also play an important role in the immunization outcome; for example, too
high a level of antigen will cause the development of low affinity antibodies. While we
found that an increasing antigen dosing profile can produce higher antibody titers, two
important questions were not answered: 1) What is the dosing kinetic scheme that also
leads to high affinity antibodies, not just higher titers? 2) Are there dosing kinetic schemes
that are even more efficient than the exponentially increasing scheme that we studied?
The possibility of an optimal dosing profile is suggested by the fact that intermediate
antigen concentrations lead to the highest affinity antibodies (24) and that an optimal
dosing profile may be one that matches the kinetics of dosing with the natural time scales
of the GC reaction. Answering these questions will require that a large parameter space
of dosing intervals and kinetic patterns be explored. Future studies are also needed to
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determine whether these profiles increase the rate of somatic hypermutation, which is
known to be important in HIV protection.
For widespread prophylactic vaccines meant for global distribution, it is impractical to
envision vaccine regimens based on a daily series of injections, especially in the
developing world where access to healthcare system can be challenging. Thus, an
important next step for the concepts presented here will be implementation of vaccine
delivery methods that allow vaccine exposure patterns as described here to be achieved
following a single administration. Methods that may be suitable include the use of
microneedle patches, biodegradable microparticles, or other controlled-release devices
(52-55). Such delivery systems have been shown to be able to deliver large proteins and
other vaccine components in increasing dose profiles. They are also well-characterized,
have in some cases been commercialized, and their release kinetics are generally well
understood (56, 57).
In summary, we have demonstrated that prolonged vaccine exposure during germinal
center induction leads to enhanced GC B-cell differentiation and antigen-specific antibody
production. Computational modeling suggested this effect was driven by enhanced
capture of antigen in lymph nodes by evolving higher-affinity antibodies early in the GC
response, a prediction borne out by experimental measurements of antigen retention in
lymph nodes. To our knowledge, this work is the first to demonstrate a key role for vaccine
kinetics in the response of B cells to immunization, and may prove to be an effective
method for increasing the efficacy of subunit vaccines.
Materials and Methods
Materials
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His-tagged Gpl 20 was expressed in HEK293 cells in serum-free media for one week and
the supernatant was purified with Talon metal affinity chromatography resin (Clontech)
followed by size-exclusion chromatography. The plasmid used was from Mata-Fink et al
(25). BG505 SOSIP.664 trimers were expressed in HEK293 cells expressing the SV40
large T-antigen (HEK293T) or Chinese hamster ovary (CHO) cells and purified with a
2G12 mAb-affinity column followed by size-exclusion chromatography as previously
reported (28, 58). Poly-L-Lysine hydrobromide (MW 500-2000) and monophosphoryl lipid
A (MPLA) from Salmonella enterica serotype Minnesota Re 595 were purchased from
Sigma-Aldrich. Bovine serum albumin (BSA; IgG-free) and HRP-conjugated goat anti-
mouse IgG, Fc fragment specific (HRP-IgG) were purchased from Jackson
ImmunoResearch. IRDye 800CW-NHS was purchased from LI-COR Biosciences. HRP-
conjugated goat anti-human IgG and Fc fragment-specific (HRP-IgG) Anti-human HRP-
IgG were purchased from Fisher Scientific. 3,3',5,5'-Tetramethylbenzidine (TMB) was
purchased from eBioscience.
Vaccination and sample collection
All procedures used in animal studies were approved by the Committee on Animal Care
at the Massachusetts Institute of Technology and the La Jolla Institute for Allergy and
Immunology Animal Care Committee and were consistent with local, state, and federal
regulations prior to initiation of this research. Female C57BL/6 mice (8-10 weeks old,
Jackson Laboratories) were subcutaneously (s.c) injected at the base of the tail with
indicated doses of gp120 and MPLA in 100 pL phosphate-buffered saline (PBS) at the
specified doses and days. This injection location drains to the inguinal lymph nodes,
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which were collected post-mortem for certain analyses. Alternatively, mice were injected
via intramuscular with gpl20 formulated in 100ug Alum (Adju-Phos®, Brenntag Biosector
A/S).
For SOSIP trimer immunizations, 6-8-week-old 129S1/SvlmJ mice (Jackson
Laboratories) were used. Mice were given interscapular bolus immunizations with 20 tg
BG505 SOSIP.664 gp140 in 0.5 Units of ISCOMATRIX (CSL Ltd.). Osmotic pumps
containing 100 Vtg (2-week slow release) or 50 pg (1-week slow release) BG505
SOSIP.664 gp140 in 0.5 Units of ISCOMATRIX were subcutaneously implanted in the
interscapular region. Blood (from retro-orbital or submandibular; 100 pL) was collected
weekly into serum separator tubes (BD Corporation) and centrifuged at 4,000 rpm for 10
min at 4*C. Alternatively, blood was collected in Eppendorf tubes and centrifuged at
13,000 rpm for 30 minutes at 4*C. Sera extracted from blood samples were stored at -
800C until ready for analysis.
ELISA
Serum anti-gp120 IgG antibodies were quantified by endpoint enzyme-linked
immunosorbent assay (ELISA) using gp120 as the capture antigen on 96-well Maxisorp
microtiter plates (Nunc). Plates were incubated with 0.5 mg/mL poly-L-lysine in PBS for
4 hrs at room temperature, blocked by 1% BSA in PBS overnight at 4 0C and incubated
with 50 nM gpl20 in PBS with 1% BSA for 2 hrs at room temperature. Mouse sera was
diluted in PBS with 1% BSA at 1:3000 or 1:30000 and incubated for 1.5 hr at 250C
followed by HRP-conjugated goat anti-mouse IgG (1:5000 in PBS with 1 % BSA) for 1 hr
at 250C. Plates were washed 4 times in between each step with 0.05% tween-20 in PBS.
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Plates were developed with TMB, stopped with 1 M sulfuric acid and read at 450 nm and
570 nm using a Tecan M1000 plate reader. Anti-gp120 IgG antibody concentrations were
calculated based on ELISA standards using mb12, a monoclonal murine antibody from
the NIH AIDS Reagent repository. Analysis was done by subtracting the 570 signal from
the 450 nm signal, fitting the standard to a four-parameter log-logistic model with the drc
package in R, and using that fit to compute antibody concentrations.
Serum anti-BG505 SOSIP.664 gp140 IgG titers were quantified as previously described
(39). Briefly, 96-well MaxiSorp plates (Thermo Scientific) were coated with 5 ptg/ml D7324
(Aalto Bio Reagents Ltd) overnight at 4C. After blocking with 2% skim milk, 0.3 pig/ml C-
terminus D7324-tagged BG505 SOSIP.664 trimers were added followed by mouse serum
and HRP-labeled goat anti-mouse IgG, Fcy fragment specific (Jackson
ImmunoResearch) with washes in between each step. For V3 specific ELISAs, plates
were coated overnight at 40C with 2 ig/ml BG505 V3 peptide
(TRPNNNTRKSIRIGPGQAFYATG) in PBS. After blocking, mouse serum was added
followed by HRP-labeled goat anti-mouse IgG with washes in between each step.
Colorimetric detection was performed using a TMB substrate kit (Thermo Scientific) and
stopped with 2N sulfuric acid. Absorbance was read at 450 nm. Endpoint titers were
calculated in GraphPad Prism after subtracting the average background optical density
(OD) from all values measured at 450 nm.
Flow cytometry analysis of lymph nodes
Inguinal and brachial lymph nodes were harvested and single cell suspensions were
obtained by passage of the lymph nodes though a 70um filter (BD Biosciences). Cells
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were washed with PBS and labeled with Live/Dead Aqua (Life Technologies) for 15 min
at 25'C. For B-cell activation and germinal center analysis, samples were treated with
anti-CD16/32 (TruStain fcX, BioLegend), followed by staining with anti-CD3e-PerCP-
Cy5.5 (BD Biosciences), anti-B220-PE-Cy7 (eBioscience), anti-CD138-PE (BD
Biosciences), anti-IgD-APC (eBioscience), anti-GL7-FITC (BD Biosciences), anti-MHCII-
AF700 (BioLegend), anti-CD86-V450 (BD Biosciences) and PNA-biotin (VectorLabs) +
Streptavidin-APCeF780 (eBioscience). CXCR5 stains were performed as previously
described (59). Flow cytometry was carried out on a BD LSR Fortessa or LSR 11.
Histology of lymph nodes
Inguinal lymph nodes were harvested, embedded in OCT compound, and frozen on dry
ice. Frozen tissues were sectioned at 10 um thickness, fixed with 4% PFA, and stained
with biotinylated anti-B220 (BioXCell), Streptavidin-APC (BD Biosciences), anti-GL7-
FITC (BioLegend) and anti-FITC-AF488 (Jackson ImmunoResearch) for germinal center
visualization. Samples were imaged with a PerkinElmer Ultraview Spinning Disk
Confocal using a 40x oil objective with a Hammamatsu ORCA-ER CCD camera.
Antigen draining experiments
Gp120 was labeled with IRDye 800CW-NHS (LI-COR Biosciences) following the
manufacturer's instructions. Subsequently mice were vaccinated with labeled gp120 in
the same manner as before according to the dosing profiles in Fig. 4. Mice were sacrificed
and their inguinal lymph nodes were removed. The lymph nodes were digested and
fluorescence was measured using a LI-COR Odyssey CLx Infrared Imaging System (LI-
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COR Biosciences). Alternatively, mice were vaccinated with intact Phycoerythrin (PE)
protein and MPLA as per the aforementioned exp-inc dosing profile or bolus injections,
and with 10 pg of BV421 labelled anti-CD21/35 antibody (to label the follicular dendritic
cells in vivo) 48 hr following the bolus or 48 hr following the last exp-inc injection. Sixteen
hours after anti-CD21/35 injections, mice were euthanized and lymph nodes were
extracted and processed to visualize the sub-nodal distribution of PE relative to FDC in
whole intact lymph nodes using the 3DISCO tissue-clearing method (60). Briefly, lymph
nodes were fixed in 4% paraformaldehyde for 2 days, washed and cleared using the
DISCO solvents, and subsequently imaged using an Olympus Fluoview FV1200
microscope equipped with 30X (NA 1.05) objective. The images were then processed
and reconstructed using Fiji image analysis software. Z-stacks were acquired for
individual FDC clusters. Maximum intensity projections were prepared to show the
distribution of antigen across the cluster.
Germinal center model calculations
The computational model coarse-grained antigen transport/clearance, the germinal
center reaction and antibody production by plasma cells. The model is expressed in terms
of a set of chemical reactions between species, including the four key reactions detailed
in Figure 3B. Parameters used for the model were collected from the literature and are
listed in Table 2, with the exception of the plasma cell antibody secretion rate k. This
single parameter was fit to reproduce the 5 IgG measurements made at day 7 and day
14 from each dosing strategy. The confidence interval of the best-fit parameter was
1.89*106 - 3.16*106. Measurements before the boost injection at day 21 were chosen to
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fit the parameter since the model does not include memory B cells and thus, the effect of
their reactivation upon boost. Evolution of these reactions in time was determined by
computationally solving a set of partial differential equations describing the temporal
evolution of these reactions (Table 2.3) using Matlab; the results were robust with respect
to a range of initial conditions.
Table 2.3. The equations underlyinq the computational model.
Time from initial injection < 6 days
dCA 9 = F(t) - DAgCAg 
- flCAgCIgnm
dt
dt = flCgCIgM - DIcCIc
dCIgM
dt = fllCAYCPM - DAb CIflM
dCIgG 0
dt
Time from initial injection 6 days
-C=Ag F(t) - DAgCAg - (f3 2 CAgCgG + J31CA9CI M)
dti
d C1~.
dt = (/2CYCIgG + PiCAgCIgM) - DcCIc - 32yCtc
dCIgM
d = 3l1CAgCgM 
- DAIJCIgMdt
dt = /?2 CAgCIgG -DAb CIgM + kCpc
= -f2yCic - DcCcdt
Statistical Analysis
Error bars are given as standard error of the mean of the log-transformed data. Kruskal-
Wallis test with Dunn's post-hoc test, or two-way analysis of variance (ANOVA) with
Dunnett's post-hoc test was used to account for multiple comparisons in computing
confidence intervals. p values were determined by unpaired Mann-Whitney test. Data was
plotted and analyzed with GraphPad Prism and R.
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Chapter 3: Chlorotoxin-siRNA conjugate delivery to brain tumors
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Overview
Glioblastoma is an aggressive type of brain tumor with a high mortality rate. It has an
incidence rate of 5.26 per 100,000, and is the most common primary malignant brain
tumor(2). Despite recent advances in treatment, it remains a disease with high mortality.
In a recent analyses of cases in the Netherlands and the US, the two-year survival
remains at approximately14% and five-year survival is less than 5%(3, 4). This is due to
several factors, including its resistance to current treatments and the inherent difficulty of
neurosurgery(2). Approaches that tackle the disease at the molecular level through
altered expression of oncogenes and other proteins contributing to drug/radiation
resistance can potentially provide new opportunities for treatments that result in better
outcomes for patients(5).
Small interfering RNAs (siRNAs) are a class of nucleic acid drugs that can be used to
decrease expression of specific genes using the RNA interference pathway(6). In brief,
when short, double-stranded RNA is in the cytoplasm, it is cleaved by a protein complex
called DICER. One strand is then loaded onto the RNA-induced silencing complex
(RISC), which finds and cleaves mRNAs complementary to the loaded strand. This leads
to sequence-specific knockdown of the targeted gene. Due to the versatility of this
pathway, siRNA can be used to treat a wide variety of diseases caused by overexpression
of a gene.
However, siRNA itself is a highly-charged molecule that does not cross biological
membranes and is excreted from the kidneys(7). The major barrier to using siRNA as a
treatment in the clinic is primarily delivery into the correct cell type. Many delivery
technologies have been evaluated for delivering siRNA to tissues of interest. These
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include viral vectors, lipid and polymer nanoparticles, polyplexes, and conjugates to small
molecules, proteins, and aptamers(7-9). While these technologies have been successful
in delivering siRNA to the liver, endothelium, and subcutaneous tumors, there has been
limited success in delivery siRNA through the blood-brain barrier. There has been even
less reported success in delivering siRNA to orthotopic brain tumors in animal models(8).
Since the nucleic acid sequence generally does not affect the transport properties of
siRNA, technologies that enable delivery could be used to knock down a wide range of
genes. Thus, siRNA could be deployed against single or multiple gene targets in a wide
range of processes in cancer, including genes involved in remodeling, metastasis, and
growth(5).
Development of siRNA conjugates
We chose to develop siRNA conjugate systems because some of the leading siRNA
clinical candidates are conjugates of siRNA with a triple galactose-N-acetaldehyde
(GaINAc) ligand that is effective in delivering siRNA to the liver(10). Furthermore,
conjugates have a defined chemical structure allowing for easier manufacturing and
quality control. Also, smaller siRNA conjugates are more likely to cross the blood-
brain/blood tumor barrier. Lastly, conjugates can also be administered subcutaneously,
which is more pleasant for the patient compared to intravenous administration, which is
required for many nanoparticle siRNA formulations.
To develop a conjugate delivery system for siRNA to brain tumors, we turned to molecular
imaging agents that have been shown to target brain tumors. Chlorotoxin is a 4 kDa
peptide derived from the venom of the Leiurus quinquestriatus scorpion(1 1, 12). It has
been shown to traffic through the blood-brain barrier and bind to a variety of tumors due
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to its affinity for MMP-2 and Annexin A2(11, 13). Indeed, one study found chlorotoxin
binding in 34 categories of tumors, which include brain, skin, prostate, breast, and
colorectal cancers, among others(11). Currently, BLZ-100, which is Cy5.5-labeled
chlorotoxin, is in clinical trials for fluorescently "painting" skin, central nervous system,
and other solid tumors so that surgeons can visualize the tumor margin(14). Other
imaging agents are being developed as well(15).
Chemistry of siRNA conjugates
The generic reaction scheme for the synthesis of chlorotoxin (CTX)-siRNA conjugates is
outlined in Figure 3.1. Briefly, we attach a PEG-azide to CTX through an amine, and then
react the CTX-PEG-azide with DBCO-modified siRNA to form the conjugate. We chose
to use strain-promoted azide-alkyne cycloaddition for the conjugation due to its high yield,
bioorthogonality, and to protect the siRNA and CTX from denaturing in other solvents(1 6).
PEG linkers were chosen for their biocompatibility and flexibility. Following synthesis,
CTX-PEG-azide and CTX-PEG-siRNA conjugates were assayed for purity using RP-
HPLC and for molecular weight using MALDI-TOF, confirming the desired CTX-siRNA
conjugates (Figure 3.2).
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Figure 3.1. Synthesis of chlorotoxin-siRNA conjugates.
a) Schematic of the chlorotoxin-PEG-siRNA conjugate with scale bar. b) Reaction scheme to
synthesize chlorotoxin-siRNA conjugates. Briefly, CTX was reacted with NHS-PEG-Azide to
yield CTX-PEG-Azide. This was purified by RP-HPLC to yield singly labeled CTX. CTX-PEG-
Azide was then reacted with DBCO-siRNA to yield CTX-PEG-siRNA, which was further
purified by RP-HPLC. CTX, chlorotoxin. c) Schematic of how the drug delivery system works.
siRNA cannot pass through the blood-brain barrier due to its size and charge. However, CTX-
PEG-siRNA is transcytosed through the brain endothelium, likely through interaction with
ANXA2 or some other protein, and then it binds to MMP2 on tumors. It is then endocytosed,
survives the endosome due to the stability of the siRNA, and is released into the cytoplasm,
where it can knock down the gene of interest.
In vitro testing of siRNA conjugates
To determine whether or not the conjugates entered cells, we synthesized conjugates
with Cy5.5-labeled siRNAs and dosed U87-MG cells (a common human glioblastoma cell
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Figure 3.2. Characterization of chlorotoxin conjugates.
a) RP-HPLC analysis of CTX-PEG4-azide on a Waters LC/MS. b) MALDI-TOF trace of CTX-
PEG4-azide. C) RP-HPLC analysis of CTX-PEG4-AHAl. d) MALDI-TOF trace of CTX-PEG4-
azide. First peak from left is single-stranded CTX-PEG4-AHA l-antisense strand. Second peak
labeled is double-stranded CTX-PEG4-AHAl. Note that double-stranded RNA is much less
stable under MALDI conditions and thus the peak at 18049 is much smaller. Matrix used was
HPA.
line(17)) transfected with Luc and GFP for 1 hr with 1 pM of fluorescent conjugate or
unconjugated fluorescent siRNA. The cells were then imaged to determine whether the
conjugates were endocytosed by the cells (Figure 3.3A). From the obtained images, we
can observe that more of the CTX-PEG4-siRNA conjugates were endocytosed relative to
the unconjugated siRNA.
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We then synthesized a series of CTX-PEG-siRNA conjugates with PEG linkers of 4, 12,
and 24 units long to optimize the linker length. The siRNA we used targeted the human
activator of 90 kDa heat shock protein ATPase homolog 1 (AHA1) gene(18, 19). We
chose this siRNA because AHA1 is widely expressed in most cell types. Furthermore, this
siRNA was chemically stabilized against degradation by nucleases in vivo, which is an
important consideration for conjugates(20). To test knockdown, we treated U87MG-Luc-
GFP cells for 72 hours with the conjugates (Figure 3.3B). Our results suggest that there
is dose-dependent knockdown of the AHAI mRNA in the chlorotoxin conjugates, with the
most knockdown observed in the CTX-PEG4-AHA1 conjugate (at 5 pM, 46% for PEG4,
7% for PEG12, 24% for PEG24). We did not observe significant knockdown for
unconjugated AHA1 siRNA (0% at 2.5 uM).
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Figure 3.3. In vitro performance of CTX-PEG-siRNA conjugates.
a) Confocal images of U87MG-Luc-GFP cells treated with CTX-PEG-AHA1-Cy5.5
conjugates (bottom) or AHA1 -Cy5.5 (top) for 1 hour at 1 pM. Red is the siRNA, green is
the cell (GFP expressed in the cell and WGA-488 staining cell membrane
glycoproteins), and blue is the nucleus (NucBlue dye). b) Relative AHA1 mRNA in
U87MG-Luc-GFP cells treated with CTX-PEG-AHA1 conjugates for 72 hours as
measured by the Quantigene mRNA assay. Untreated U87MG-Luc-GFP cells have an
mRNA level of 1. mRNA levels were normalized for cell number by ACTB mRNA levels.
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In vivo testing of conjugate biodistribution to intracranial tumors
We next evaluated the lead CTX-PEG4-siRNA conjugate vivo using a U87MG-Luc-GFP
cell line which allows for cellular visualization through imaging of luciferase and GFP
expression. To model tumors in the brain, we implanted the cells intracranially in nude
mice and allowed them to develop into tumors. To determine whether the siRNA trafficked
to the tumor, we injected the mice either subcutaneously (s.c) or intravenously (i.v.) with
Cy5.5-labeled siRNA or conjugates and then removed the tumor and part of the brain
after 24 hours. The tissue was dissociated and analyzed by flow cytometry to determine
whether the siRNA was present in the tumor cells. Figure 3.4B shows that CTX-siRNA
conjugates have greatly improved trafficking to the tumor compared to unconjugated
siRNA (mean fluorescence 3216 vs 925, p = 0.002) while sparing most mouse cells (3216
vs. 235, p < 0.001). Furthermore, we observed that s.c. administration is not significantly
different in efficacy to i.v. administration (mean fluorescence 3216 vs. 3789, p=0. 2 8). We
proceeded with s.c. administration as it is easier for patients to self-administer than i.v.
injections.
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We then investigated the pharmacokinetics of the siRNA in the tumor after s.c.
administration. Mice with or without tumors were treated with either CTX-PEG4-siRNA-
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Figure 3.4. In vivo targeting of CTX-PEG-siRNA conjugates to tumor cells in a mouse model
of glioblastoma.
Six-week-old nu/nu mice were injected intracranially with U87MG-Luc-GFP cells and treated
after the tumor reached 1.5-2 mm in size via luminescence. a) Sample histograms from flow
cytometry showing the intensity of CTX-PEG-siRNA-Cy5.5 signal vs. siRNA-Cy5.5 signal in
U87MG-GFP-Luc tumors 24 hours after s.c injection. b) Cy5.5 signal intensity in U87MG-GFP-
Luc tumors after s.c. injection of CTX-PEG-siRNA-Cy5.5, i.v. injection of CTX-PEG-siRNA-
Cy5.5, and i.v. injection of siRNA-Cy5.5. The two rightmost columns are untreated tumor and
mouse cell (GFP negative) levels from all injections of CTX-PEG-siRNA-Cy5.5. All samples
taken 24 hours post-injection. P-values from two-tailed t-tests from left to right are 0.28, 0.002,
<0.001, and <0.001. N=3. c) Sample images from IVIS 5 days post s.c. injection of 8 mg/kg of
CTX-PEG4-siRNA-Cy5.5. Scale is in radiance efficiency. d) Quantitation of max fluorescence
over 7 days post s.c. injection in the area of the tumor (as indicated by luciferase signal) or head
area for mice without tumors. NS, not significant. e) Representative images from intravital
imaging of tumor field. Green denotes the tumor cells, red denotes the CTX-PEG4-siRNA-Cy5.5
conjugates. Images were acquired 30 mins post i.v. injection of 150 ptL of 1 pLM CTX-PEG4-
siRNA-Cy5.5 solution.
Cy5.5 or siRNA-Cy5.5 and imaged using an IVIS instrument. Cy5.5 fluorescence was
measured in the region of the head where the tumor had been implanted for 8 days post-
injection. As shown in Figure 3.4D, the fluorescence signal is much stronger in mice with
tumors (Day 1 epifluorescence, tumors + CTX-si: 29.5x10-6, tumors + si 5.7x10-6, no
tumor + CTX-si: 7.0x10-6, control mice O.9x10-6), and the siRNA persists for at least one
week in the tumor (Day 8 epifluorescence, tumors + CTX-si: 5.3x10-6, tumors + si 3.1x10~
6, no tumor + CTX-si: 1.4x10-6). Figure 3.4C shows images from some of the mice on
day 5, and although the fluorescence is much lower than day 1, the siRNA is still primarily
in the mice with tumors that were treated with CTX-PEG4-siRNA conjugates.
Furthermore, we used intravital imaging to understand how the siRNA is distributed
throughout the tumor and whether it can penetrate the tumor. Briefly, mice were
anesthetized, a craniotomy was performed, and a slide was placed over the tumor. A
multiphoton microscope was used to image the tumor tissue. Figure 3.4E contains
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representative wide-field images which show that the conjugate is indeed found within a
wide section of the tumor.
Knockdown of housekeeping genes in vivo using conjugates
Lastly, we measured RNA knockdown (KD) of our target gene (AHA1) in brain tumor
xenografts. This was done 72 hours post-injection, to allow time for trafficking and
knockdown. Figure 3.5 shows 7% reduction in AHA1 mRNA in the groups treated with
unconjugated siRNA, which was not statistically significantly different from untreated
(p=0.55). However, there was a dose-dependent and statistically significant reduction (8
mg/kg: 31% KD, p=0.024; 16 mg/kg: 49% KD, p=0.001) in AHA1 mRNA in the groups
treated with CTX-PEG4-siRNA conjugates. This demonstrates that we can successfully
knock down genes in a mouse xenograft model of brain tumors.
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Figure 3.5. In vivo knockdown efficiency in tumor of CTX-PEG4-siRNA conjugates.
Six-week-old nu/nu mice were injected intracranially with U87MG-Luc-GFP cells and treated
after the tumor reached 1.5-2 mm in size via luminescence. Mice were injected s.c. with CTX-
PEG4-AHA1 or unconjugated AHAl at the specified doses (N=5 for treatment groups, N=9 for
untreated). For comparison purposes, doses only consider the mass of the siRNA, not the
conjugate. Mice were sacrificed 72 hours post injection, and tumor was resected. mRNA from
the tumor was quantified by the Quantigene 2.0 assay using a human-specific probe to probe
knockdown in the U87MG-Luc-GFP cells. Untreated tumors have an mRNA level of 1. mRNA
levels were normalized for cell number by ACTB mRNA levels. The untreated group was
significantly different from the 8 mg/kg CTX-PEG4-AHIA1 group (31% KD, p=O.024, t-test,
two-tailed) and the 16 mg/kg CTX-PEG4-AHA1 group (49% KD, p=0.00 1), but not the 8 mg/kg
siRNA alone group (7% KD, p=0.548). NS, not significant; KD, knockdown.
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Application to CYCLOPS genes
We also attempted to apply the conjugates to a disease-modifying siRNA. Work
by Rameen Beroukhim's lab at the Dana Farber Cancer Institute and Broad Institute has
shown that RNAi suppression of critical genes that have lost alleles in tumors could be
used to kill tumors. These genes, called CYCLOPS genes, are genes that are critical for
cell survival and have only one allele present in the cell due to aneuploidy or mutations.
Because of this, lower levels of suppression of protein production may be able to
decrease survival of the tumor. The system had been proved in vivo using genetically
modified tumor lines that included Dox-inducible shRNA(21). After administering
doxycycline to the mice, there was dose-dependent knockdown of a putative CYCLOPS
gene and subsequent reduction in tumor size in the vulnerable cell line. From their
publication, for one of the genes, it appeared that the knocking down 50% of the mRNA
is enough to get 75-90% loss of cell viability. Since this appeared to be a limit on the
amount of knockdown we could obtain with the chlorotoxin-siRNA system, we decided to
see if CYCLOPS genes could have a therapeutic effect.
Table 3.1. CYCLOPS genes identified for U87MG cell line
Gene Function Prevalence
PABPN1 Part of a complex that adds poly-A tails to mRNA 21% of cancers
30% of GBM
DNAJA3 Mitochondrial chaperone involved in protein folding 16% of cancers
and degradation 11% of GBM
SNRPB/C Required parts of the spliceosome 10/13% of
cancers
3/13% of GBM
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In collaboration with a postdoc (Brenton Paolella) in his lab, we have identified
CYCLOPS genes in the U87 cell line. Table 3.1 lists some of the genes that Brent
identified for U87 cells that fulfilled criteria for being CYCLOPS genes.
We purchased siRNAs against these genes from Axolabs GmBH. After screening a
variety of siRNAs against these 4 targets in vitro, I identified the most potent ones and
treated cells with them. Because CYCLOPS genes are ones that have lost alleles, the
control we used was the diploid cell line Cal5l, a breast cancer line. To determine which
CYCLOPS gene had maximal cytotoxicity, I treated U87 and Cal5l cells with a range of
doses of the siRNA with Lipofectamine, and then measured cell viability after 72 hours.
The results are shown in Figure 3.6.
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Figure 3.6. In vitro performance of CYCLOPS genes on U87 cells.
Cal51 and U87 cells were plated in 96 well plates at 20,000 per well. Cells were treated with
dilutions of siRNA- Lipofectamine RNAiMax lipoplexes created following manufacturer's
instructions at the specified siRNA concentration (N=2). Viability was measured 72 hours later
using the Cell-Titer Glo assay.
Afterwards, PABPN1 was identified as the optimal conjugate and tested in U87
tumor-bearing nu/nu mice in vivo. Unfortunately, as seen in Figure 3.7, it did not have a
significant effect on tumor growth. This is likely due to the extremely fast growth rate of
the U87 model and glioblastomas in general. Because we are likely to only get an -50%
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reduction in viability in those cells that exhibit knockdown during the procedure, even
though we transfect twice, the cells that were not transfected grow faster and outcompete
those that do.
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Figure 3.7. In vivo testing of CTX-AHA1 vs CTX-PABPNI.
Mice bearing U87 intracranial tumors were treated subcutaneously with CTX-AHA1 or
CTX-PABPN1 at 16 mg/kg on day 4 and day 11 post tumor inoculation. Tumors were
imaged using BLI and the IVIS system over 14 days. Y axis is ratio of tumor size at first
treatment to tumor size at day 19.
In summary, we present the development of a brain-tumor targeted siRNA
conjugate that can knock down genes in vivo. This is a platform that can be used to deliver
siRNA against a wide variety of genes into tumor cells in vivo after subcutaneous injection.
As chlorotoxin has affinity for many other types of tumors, including breast, ovarian,
prostate, and others, this delivery system could be adapted for other tumor types as
well(1 1). We believe this to be the first instance of systemic subcutaneous siRNA delivery
and knockdown in an orthotopic mouse xenograft brain tumor model. The ability to
specifically deliver siRNA to cancer cells in the brain without the need for a carrier is a
powerful new tool for the development of next generation therapies for brain tumors.
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Materials and Methods
Synthesis of siRNA-chlorotoxin conjugates
10 mg Chlorotoxin (Alomone Labs, Jerusalem, Israel) was solubilized in ph 8 phosphate
buffer at 5 mg/mL. 1.7 mg NHS-PEG-Azide (Quanta BioDesign, Plain City, OH) was
dissolved in 222 pL of DMSO and added to the chlorotoxin solution with mixing. The
solution was reacted at 4 C overnight and purified by RP HPLC using 1.5% Acetic
acid/Acetonitrile phases with a Waters C18 Xbridge Peptide BEH 300A, 3.5 pm column
followed by lyophilization to yield fractionated chlorotoxin-PEG-azide. Fractionated
chlorotoxin-PEG-azide was solubilized in RNAse-free water and analyzed by LC/MS
(Waters) to determine purity and molecular weight.
Dibenzylcyclooctyne (DBCO) modified siRNA (Axo Labs, Kolmbach, Germany) was then
added to the purified chlorotoxin-PEG-azide fractions at a 1:1 stoichiometric ratio and
reacted overnight at RT to yield chlorotoxin-PEG-siRNA conjugates. Conjugates were
purified by RP-HPLC on the same column using 0.1 mM triethylamine-acetic-
acid/Acetonitrile phases and analyzed by MALDI-TOF and RP HPLC to determine purity
and molecular weight.
Generation of U87MG-Luc-GFP cell line
HEK-293T cells were transfected with pMLS-GFP- Luciferase, VSVG and Gag/Pol
packaging vectors using the viral supernatant. The pMLS-EGFP- Firefly Luciferase
plasmid was a gift from Michael Yaffe. The viral supernatant was used to transduce
U87MG (ATCC) cells for stable expression of EGFP and firefly luciferase. Cells were used
for intracranial orthotopic injections after at least 3 passages to dilute out any remaining
unintegrated virus particles
90
In vitro knockdown assays
U87MG-Luc-GFP cells were seeded in a 96-well plate at 25,000 cells per well.
Chlorotoxin-PEG-siRNA was added to the cells and left for 72 hours. After 72 hours, the
AHA1 and ACTB mRNA content of the cells was analyzed using the Quantigene mRNA
assay (Affymetrix) according to the manufacturer's instructions. In the analysis, AHA1
mRNA levels were normalized by ACTB mRNA levels to account for variations in cell
loading.
In vitro imaging
U87 cells were plated in an 8-well LabTek 11 Chamberslide (Nunc) at 25,000 cells per
well. After 24 hours, cells were treated with chlorotoxin-PEG-siRNA-Cy5.5 conjugates at
500 nM. After 1 h, cells were washed twice gently with 37 C PBS, fixed in 4%
paraformaldehyde solution (Electron Microscopy Sciences) for 10 mins at RT, washed
thrice with RT PBS, stained with WGA-488 (Invitrogen) and NucBlue Fixed Cell Stain
(Invitrogen) for 20 mins, and washed thrice with RT PBS. The chambers were then
removed, and a coverslip was mounted on the slide with Prolong Diamond Antifade
(Invitrogen). The slide was left to dry for 48 hours and then imaged on an Olympus
FV1200 confocal microscope.
In vivo tumor implantations and experiments
U87-Luc-GFP cells were implanted in 6-8-week-old female nude mice (Charles River) via
intracranial injections. An incision was made across the top of the skull, and a small hole
was carefully drilled through the skull 2 mm to the right and 2mm caudal to the bregma
using an 18G needle. This location was chosen as it is a typical location for tumors to
form in patients(22). 150,000 U87MG-GFP-Luc cells in 3 pL PBS were injected over the
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course of 3 minutes 3 mm deep into the brain using a Hamilton Neuros Model 75 blunt
end 5 pL syringe. The needle was allowed to rest for one minute, and then slowly retracted
over 30 seconds. The hole was immediately filled with bone wax, and the incision was
closed with Vetbond tissue adhesive (3M). Tumors were measured as they grew via
luminescence: mice were injected intraperitoneally (i.p.) with 150 pL of 15 mg/mL D-
luciferin solution (Perkin Elmer) and were imaged in an IVIS machine 10 minutes post
injection for 1 s at medium binning. Mice were treated after the luminescent signal
exceeded 1x108 photons/mmA2, as this generally correlated with a tumor size of about
1.5-2 mm. Depending on the experiment, mice were injected either intravenously via the
tail vein or subcutaneously at the nape of the neck with the materials of interest.
Flow cytometric analysis of tumors
Mice were sacrificed and tumors were removed and kept on ice in DMEM. Tumors were
then dissociated using a mouse tumor dissociation kit (Miltenyi Biotec) according to
manufacturer's instructions. Cells were filtered through a 35-micron filter to obtain a single
cell suspension, washed thrice, and analyzed on a BD LSR I flow cytometer. Washes
and stains were performed in PBS with 1 % BSA and 2 mM EDTA.
Intravital imaging
Mice were injected with 150 pL of 1 pM CTX-PEG4-siRNA-Cy5.5. They were then
anesthetized with 150 mg/kg ketamine and 10 mg/kg xylazine. A craniotomy was
performed to expose the brain, and a glass cover slip was placed against the brain. The
mouse was secured with laboratory tape and placed on the heated stage of an Olympus
FV1000 Multiphoton confocal. After imaging the mouse was sacrificed. Images were
processed with the Volocity software to create maximum intensity projections.
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In vivo RNA knockdown
Mice were sacrificed, perfused with cold PBS, and tumors were removed into SPEX
sample prep tubes and immediately frozen in liquid nitrogen. Tumors were then
cryogenically ground to a fine powder using a Geno/Grinder 2000. About 3 mg of
powdered tissue was resuspended in 500 pL of Tissue Homogenization Solution
(Epicentre), and 50 micrograms of Proteinase K (Epicentre) was added. The mixture was
incubated for 2 hours at 55 C with 800 rpm shaking in 1.5 mL tubes. Afterwards, the
solution was further homogenized by sequential passage through 20, 22, 25, and 30
gauge needles. The homogenized solution was then assayed for mRNA using the
Quantigene 2.0 mRNA assay (Affymetrix). In the analysis, AHA1 mRNA levels were
normalized by ACTB mRNA levels to account for variations in cell loading.
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Chapter 4: PSMA-Ligand conjugates
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Overview
Prostate cancer is the second most common type of cancer worldwide (1).
However, it is the fifth leading cause of mortality from cancer in men (1). Currently,
incidence rates are rising around the world, especially in Asia and Europe, necessitating
the need for better methods of diagnosing and treating prostate cancer (2).
Chemotherapeutics such as doxorubicin and paclitaxel have been shown to be
effective against prostate cancer (3, 4). However, because they target rapidly-dividing
cells, chemotherapy is highly toxic and induces a wide range of side effects, including
neutropenia, organ damage, and hair loss (5). By using targeted therapy to increase the
concentration of the chemotherapeutic in the tumor, lower doses can be used to kill the
tumor while sparing healthy tissues. Thus, new methods of targeted delivery of
chemotherapeutics to prostate cancer are urgently needed.
Prostate-specific membrane antigen (PSMA) is a binuclear zinc metallopeptidase
that is normally expressed in prostate tissues and the nervous system (6). However, in
malignant prostate cancers, especially androgen resistant cancers, PSMA is expressed
at levels that increase with increasing cancer grade (7). Furthermore, PSMA expression
has been found in cancers of the kidney, bladder, breast, colon, and Schwann cells as
well(8, 9). Other work has demonstrated that PSMA is expressed in the neovasculature
of solid tumors, but not the regular tissue vasculature (9, 10). Thus, because of these
features, it has been used as an imaging agent for the diagnosis of prostate cancer (11-
13).
To create imaging agents, PSMA-directed antibodies and aptamers have mainly
been conjugated to PET and SPECT labels (11-14). Recently, a family of urea-based
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small molecule inhibitors of PSMA have been found, and have been used as imaging
agents as well (15, 16). Unlike antibodies and aptamers, these small molecule ligands
have easier access to the tumor due to their smaller size. Furthermore, because of the
structure of PSMA, large cargo can be conjugated to these urea-based molecules and
still maintain activity of the inhibitor (17). Based on these observations, we decided to use
these PSMA ligands to deliver chemotherapeutics to PSMA-expressing tumors.
PSMA Ligand conjugates
PSMA Ligand conjugates were synthesized by our collaborators at Moscow State
University. Alex Majouga's laboratory synthesized the PSMA ligand. They also
synthesized chemotherapeutic conjugates with doxorubicin and paclitaxel that were
ligated with a hydrazine linker. The drug conjugates were first solubilized in DMSO,
aliquoted, and kept at -20 C. Before usage, they were dissolved in a small amount
(typically 5 pL) of Tween 20 to aid in solubilization. For experiments, they were diluted to
a final Tween concentration of 2%. An example of one of the conjugates is shown in
Figure 4.1.
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Figure 4.1. Example of PSMA ligand conjugate.
Urea-based PSMA ligand (green) is connected through a linker (black) to doxorubicin
(red). These molecules were synthesized by Alex Majouga's laboratories.
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PSMA ligand-chemotherapeutic conjugates do not lose their efficacy in vitro
In order to determine whether conjugates of PSMA ligands are capable of killing cancer
cells, I tested the PSMA ligand-paclitaxel and PSMA-ligand doxorubicin conjugates in
vitro on 22Rv1 cells (ATCC). This cell line is derived from a human prostatic carcinoma
that was serially propagated in mice, and is known to express PSMA(18, 19). Compared
to other prostate cancer cell lines, such as LNCaP, it grew faster and was easier to
culture. The 22Rv1 cells were grown in RPMI with 10% FBS (Thermo Fisher) in Corning
TC-treated culture flasks.
The results can be found in Figure 4.2 and Figure 4.3. For the paclitaxel conjugates, these
results indicate that although the paclitaxel alone does appear to be slightly more potent,
the addition of these targeting ligands using copper-catalyzed azide-alkyne cycloaddition
does not affect the drug in a substantial manner. The ligand-targeted doxorubicin
conjugates appear to be more potent than unconjugated doxorubicin.
However, these experiments also indicate that there was not a high degree of
increased cytotoxicity from the conjugation. This indicates that the PSMA receptor is not
rapidly transporting more of the chemotherapeutic into the cell. Since PSMA is a cell-
surface enzyme that acts as a glutamate carboxypeptidase, we would not expect it to
function as a transporter (6). However, in vivo, the conjugate could still have an effect as
the conjugate could increase the local concentration of chemotherapeutic around the
cells, increasing the rate of endocytosis and cell death.
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Figure 4.2. PSMA-Paclitaxel has comparable in vitro efficacy to paclitaxel.
22Rv1 cells that express PSMA were plated at a density of 25000 cells per well. The
cells were treated with paclitaxel or conjugated paclitaxel at the specified concentrations
for 96 hours. Cell viability was measured using the CellTiter-Glo assay (Promega).
PSMA ligand-paclitaxel conjugates were synthesized by Alex Majouga's laboratory.
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Figure 4.3. Dox and Dox-PSMA ligand conjugates have similar degrees of
cytotoxicity.
22Rv1 cells that express PSMA were plated at a density of 25000 cells per well. The
cells were treated with doxorubicin or conjugated doxorubicin at the specified
concentrations for 96 hours. Cell viability was measured using the CellTiter-Glo assay(Promega). Dox-122, Dox-123, and Dox-125 are variants of the Dox-PSMA ligand
conjugates that differ slightly in chemical structure. They were synthesized by Alex
Majouga's laboratory.
In vivo testing of PSMA ligand paclitaxel conjugates
In order to determine whether there could be some in vivo activity in terms of
targeted cell killing, I tested the PSMA ligand paclitaxel conjugates on nu/nu mice with
subcutaneous flank 22Rv1 xenografts. We used the PSMA-Paclitaxel conjugates instead
of the PSMA-Dox as Majouga's laboratory made sufficient PSMA-Paclitaxel to do longer-
term animal experiments. Tumor induction was done with 2x106 freshly isolated 22Rv1
cells kept on ice in 100 pL of PBS mixed with 100 pL of Matrigel that had been thawed
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overnight at 4 C. The solution was injected into the left flank of nu/nu mice to establish
the tumor. Tumor formation was monitored using calipers, and tumor volume was
calculated using the formula wxh2x0.52, where w is the major axis of the tumor and h is
the minor axis. Treatment was initiated once the tumor reached a volume of 50 mm 3. This
took approximately three weeks.
During the treatment, either conjugated or unconjugated drug was administered
intraperitoneally very Monday, Wednesday, and Friday. Mice were monitored after
injections for any toxicity. No severe adverse events were observed during the entire
treatment period. Tumor size was measured every Monday, Wednesday, and Friday as
well for 21 days. Mice were sacrificed after the experimental endpoint by C02
asphyxiation, and tumors were removed for analysis.
The results in terms of growth of tumor can be found in Figure 4.4. It should be
noted that there was a very high degree of biological variation in terms of the tumor sizes,
indicating that future experiments should be done with higher sample sizes. However, it
is clear that untreated mice have much higher tumor volumes than either the paclitaxel or
PSMA ligand-paclitaxel groups.
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Figure 4.4. Tumor growth and variation across the different treatments.
Tumor induction was performed on nu/nu mice with 2x106 22Rv1 cells mixed with
Matrigel. Mice were treated when tumors reached 50 mm 3. 3 mg/kg PSMA ligand
paclitaxel and paclitaxel were administered IP every M,W,F after treatment initiation.
Both treatments were solubilized with 2% of Tween 20. Tumor volume measurements
were performed using calipers, and tumor volume was calculated using the formula
wxh2x0.52, where w is the major axis of the tumor and h is the minor axis. Relative
tumor volumes were calculated by dividing the measured tumor volume on that day with
the tumor volume when treatment was initiated. Sample sizes are as follows: untreated,
11; Pac, 4; PSMA-Pac, 6.
In order to overcome this variability and extract useful information from the data, I
used a mixed effect model to estimate the tumor growth rate. First, the tumor volumes
were log-transformed to reduce heteroscedasticity. Then, I fitted the data using Days and
Treatment:Days as fixed effects, and used the individual as a random effect. A general
linear hypothesis test was used to determine the effect size of the groups in terms of the
doubling rate and to determine 95% confidence intervals for this measure. The doubling
rate is plotted in Figure 4.5. Significant differences were found between the Untreated
and the Pac-PSMA and PSMA groups (p < 0.001 for both) but not between the PSMA
and Pac-PSMA groups (p = 0.98). Thus, we conclude that the PSMA ligand conjugate did
not significantly reduce tumor burden any more than unconjugated PSMA.
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Figure 4.5. PSMA Paclitaxel and PSMA have similar levels of efficacy.
Tumor induction was performed on nu/nu mice with 2x1 06 22Rv1 cells mixed with
Matrigel. Mice were treated when tumors reached 50 mm 3. PSMA ligand paclitaxel and
paclitaxel were administered IP every M,W,F after treatment initiation. Both treatments
were solubilized with 2% of Tween 20. Sample sizes are as follows: untreated, 11; Pac,
4; PSMA-Pac, 6. Tumor volume measurements were performed using calipers, and
tumor volume was calculated using the formula wxh2x0.52, where w is the major axis of
the tumor and h is the minor axis. Tumor doubling time was calculated using a linear
mixed-effects model of the form log(Relative volume) - 1 + Treatment:Days + Days with
a random individual effect. Generalized linear hypothesis testing was used to compute
the tumor doubling time and the 95% confidence intervals (error bars shown).
The fact that the PSMA-paclitaxel conjugate did not significantly decrease tumor
burden may be attributed to a variety of causes. One reason could be poor tumor
vascularization. Because the tumors in this case were not well-vascularized (not many
blood vessels were seen), it is likely that the PSMA-paclitaxel was unable to penetrate
the tumor fully. Lack of drug penetration has been observed for other tumors due to
increased intratumor pressure and solid stress, and it is well known that even small
molecules find it difficult to penetrate tumors (20, 21). Although this is not an avoidable
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problem, other xenograft models, such as LNCaP tumors, show higher degrees of
vascularization, and perhaps would be more responsive to the conjugate.
Secondly, the dose used was fairly low in the context of other studies that have
used paclitaxel in xenografts. Doses of up to 20 mg/kg have been used to allow for
adequate response. Due to the limited amount of conjugate we received, I chose to dose
at only 3 mg/kg to ensure that we would have enough for a larger number of mice (6 in
the conjugate group and 3 in the control) over a period of three weeks. The time duration
is important, as it is at the later stages of exponential growth of the tumors that the
differences become clearer between the untreated and paclitaxel treated groups (see
Figure 4.4). Hence, perhaps higher doses of the drug or more frequent dosing would
result in better performance of the conjugate.
Lastly, tumor growth rates varied greatly among the mice, even in the untreated
group. Although all mice were injected in the same method on the same day from the
same batch of cells, the tumors behaved very differently. This could be due to the
exponential nature of tumor growth: small changes in initial growth rate are amplified into
large differences in tumor size due to the rapidly proliferating nature of tumor cells.
However, because of this, sample sizes would have to be increased, perhaps to up to 15-
20 mice per group in order to have sufficient power to detect differences from noisy data.
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